NeueHealth (NEUE) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Nov. 04, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-40537
Entity Registrant Name	BRIGHT HEALTH GROUP, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-4991296
Entity Address, Address Line One	8000 Norman Center Drive, Suite 1200
Entity Address, City or Town	Minneapolis
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55437
City Area Code	612
Local Phone Number	238-1321
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	BHG
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		628,315,180
Entity Central Index Key	0001671284
Amendment Flag	false
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 956,189,000	$ 488,371,000
Short-term investments	331,719,000	499,928,000
Accounts receivable, net of allowance of $5,701 and $2,602, respectively	99,216,000	60,522,000
Prepaids and other current assets	240,545,000	130,986,000
Total current assets	1,627,669,000	1,179,807,000
Other assets:
Long-term investments	681,923,000	175,176,000
Property, equipment and capitalized software, net	30,932,000	12,264,000
Goodwill	842,301,000	263,035,000
Intangible assets, net	351,519,000	152,211,000
Other non-current assets	40,751,000	28,309,000
Total other assets	1,947,426,000	630,995,000
Total assets	3,575,095,000	1,810,802,000
Current liabilities:
Medical costs payable	685,045,000	249,777,000
Accounts payable	95,161,000	57,252,000
Unearned revenue	34,917,000	34,628,000
Risk adjustment payable	548,352,000	187,777,000
Other current liabilities	88,133,000	35,847,000
Total current liabilities	1,451,608,000	565,281,000
Other liabilities	56,254,000	28,578,000
Total liabilities	1,507,862,000	593,859,000
Commitments and contingencies (Note 10)
Redeemable noncontrolling interests	130,029,000	39,600,000
Redeemable preferred stock, $0.0001 par value; 100,000,000 and 166,307,087 shares authorized in 2021 and 2020, respectively; — and 164,244,893 shares issued and outstanding in 2021 and 2020, respectively	0	1,681,015,000
Shareholders’ equity (deficit):
Common stock, $0.0001 par value; 3,000,000,000 and 658,993,725 shares authorized in 2021 and 2020, respectively; 628,133,782 and 137,662,698 shares issued and outstanding in 2021 and 2020, respectively	63,000	14,000
Additional paid-in capital	2,823,244,000	9,877,000
Accumulated deficit	(886,333,000)	(515,989,000)
Accumulated other comprehensive income	230,000	2,426,000
Total shareholders’ equity (deficit)	1,937,204,000	(503,672,000)
Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders’ equity (deficit)	$ 3,575,095,000	$ 1,810,802,000

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts receivable, allowance for credit loss	$ 5,701	$ 2,602
Redeemable preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Redeemable preferred stock, shares authorized (in shares)	100,000,000	166,307,087
Redeemable preferred stock, shares issued (in shares)	0	164,244,893
Redeemable preferred stock, shares outstanding (in shares)	0	164,244,893
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	3,000,000,000	658,993,725
Common stock, shares issued (in shares)	628,133,782	137,662,698
Common stock, shares outstanding (in shares)	628,133,782	137,662,698

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Premium revenue	$ 1,020,233	$ 345,426	$ 2,922,950	$ 827,135
Service revenue	$ 11,079	$ 4,920	$ 31,602	$ 13,344
Revenue, Product and Service [Extensible Enumeration]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Investment income	$ 47,345	$ 1,774	$ 112,503	$ 7,063
Total revenue	1,078,657	352,120	3,067,055	847,542
Operating expenses:
Medical costs	1,050,943	311,319	2,640,143	675,114
Operating costs	309,790	97,379	779,090	260,650
Depreciation and amortization	14,205	2,678	25,981	5,550
Total operating expenses	1,374,938	411,376	3,445,214	941,314
Operating loss	(296,281)	(59,256)	(378,159)	(93,772)
Interest expense	1,594	0	6,282	0
Other income	(1,226)	0	(1,226)	0
Loss before income taxes	(296,649)	(59,256)	(383,215)	(93,772)
Income tax expense (benefit)	73	0	(18,225)	(9,162)
Net loss	(296,722)	(59,256)	(364,990)	(84,610)
Net earnings attributable to noncontrolling interests	(3,942)	0	(5,354)	0
Net loss attributable to Bright Health Group, Inc. common shareholders	$ (300,664)	$ (59,256)	$ (370,344)	$ (84,610)
Basic loss per share attributable to Bright Health Groups, Inc. common shareholders (in dollars per share)	$ (0.48)	$ (0.43)	$ (1.19)	$ (0.62)
Diluted loss per share attributable to Bright Health Groups, Inc. common shareholders (in dollars per share)	$ (0.48)	$ (0.43)	$ (1.19)	$ (0.62)
Basic weighted-average common shares outstanding (in shares)	630,378	136,337	312,294	135,926
Diluted weighted-average common shares outstanding (in shares)	630,378	136,337	312,294	135,926

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (296,722)	$ (59,256)	$ (364,990)	$ (84,610)
Other comprehensive (loss) income:
Unrealized investment holding (losses) gains arising during the year, net of tax of $0 and $0, respectively	(143)	(958)	(1,808)	2,326
Less: reclassification adjustments for investment gains, net of tax of $0 and $0, respectively	160	119	388	68
Other comprehensive (loss) income	(303)	(1,077)	(2,196)	2,258
Comprehensive loss	(297,025)	(60,333)	(367,186)	(82,352)
Comprehensive loss attributable to noncontrolling interests	(3,942)	0	(5,354)	0
Comprehensive loss attributable to Bright Health Group, Inc. common shareholders	$ (300,967)	$ (60,333)	$ (372,540)	$ (82,352)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (PARENTHETICAL) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Unrealized investment holding (losses) gains arising during the year, tax	$ 0	$ 0	$ 0	$ 0
Reclassification adjustments for investment gains, tax	$ 0	$ 0	$ 0	$ 0

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE PREFERRED STOCK AND SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	IPO	Common Stock	Common StockIPO	Additional Paid-In Capital	Additional Paid-In CapitalIPO	Retained Earnings (Deficit)	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2019	119,222,000
Beginning balance at Dec. 31, 2019	$ 871,990
Ending balance (in shares) at Mar. 31, 2020	119,222,000
Ending balance at Mar. 31, 2020	$ 871,990
Beginning balance (in shares) at Dec. 31, 2019			135,509,000
Beginning balance at Dec. 31, 2019	(263,367)		$ 14		$ 3,184		$ (267,547)	$ 982
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(7,280)						(7,280)
Issuance and sale of common stock (in shares)			183,000
Issuance and sale of common stock	13				13
Share-based compensation	943				943
Other comprehensive income (loss)	951							951
Ending balance (in shares) at Mar. 31, 2020			135,692,000
Ending balance at Mar. 31, 2020	$ (268,740)		$ 14		4,140		(274,827)	1,933
Beginning balance (in shares) at Dec. 31, 2019	119,222,000
Beginning balance at Dec. 31, 2019	$ 871,990
Ending balance (in shares) at Sep. 30, 2020	162,179,000
Ending balance at Sep. 30, 2020	$ 1,638,830
Beginning balance (in shares) at Dec. 31, 2019			135,509,000
Beginning balance at Dec. 31, 2019	(263,367)		$ 14		3,184		(267,547)	982
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(84,610)
Other comprehensive income (loss)	2,258
Ending balance (in shares) at Sep. 30, 2020			136,820,000
Ending balance at Sep. 30, 2020	$ (341,123)		$ 14		7,780		(352,157)	3,240
Beginning balance (in shares) at Mar. 31, 2020	119,222,000
Beginning balance at Mar. 31, 2020	$ 871,990
Redeemable Preferred Stock
Issuance of preferred stock (in shares)	19,661,000
Issuance of preferred stock	$ 291,200
Ending balance (in shares) at Jun. 30, 2020	138,883,000
Ending balance at Jun. 30, 2020	$ 1,163,190
Beginning balance (in shares) at Mar. 31, 2020			135,692,000
Beginning balance at Mar. 31, 2020	(268,740)		$ 14		4,140		(274,827)	1,933
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(18,074)						(18,074)
Issuance and sale of common stock (in shares)			246,000
Issuance and sale of common stock	118				118
Share-based compensation	1,250				1,250
Other comprehensive income (loss)	2,384							2,384
Ending balance (in shares) at Jun. 30, 2020			135,938,000
Ending balance at Jun. 30, 2020	$ (283,062)		$ 14		5,508		(292,901)	4,317
Redeemable Preferred Stock
Issuance of preferred stock (in shares)	23,296,000
Issuance of preferred stock	$ 475,640
Ending balance (in shares) at Sep. 30, 2020	162,179,000
Ending balance at Sep. 30, 2020	$ 1,638,830
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(59,256)						(59,256)
Issuance and sale of common stock (in shares)			882,000
Issuance and sale of common stock	743				743
Share-based compensation	1,529				1,529
Other comprehensive income (loss)	(1,077)							(1,077)
Ending balance (in shares) at Sep. 30, 2020			136,820,000
Ending balance at Sep. 30, 2020	$ (341,123)		$ 14		7,780		(352,157)	3,240
Beginning balance (in shares) at Dec. 31, 2020	164,244,893
Beginning balance at Dec. 31, 2020	$ 1,681,015
Redeemable Preferred Stock
Issuance of preferred stock (in shares)	1,420,000
Issuance of preferred stock	$ 55,137
Ending balance (in shares) at Mar. 31, 2021	165,665,000
Ending balance at Mar. 31, 2021	$ 1,736,152
Beginning balance (in shares) at Dec. 31, 2020	137,662,698		137,663,000
Beginning balance at Dec. 31, 2020	$ (503,672)		$ 14		9,877		(515,989)	2,426
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(25,162)						(25,162)
Issuance and sale of common stock (in shares)			4,661,000
Issuance and sale of common stock	4,893				4,893
Share-based compensation	5,176				5,176
Other comprehensive income (loss)	(1,042)							(1,042)
Ending balance (in shares) at Mar. 31, 2021			142,324,000
Ending balance at Mar. 31, 2021	$ (519,807)		$ 14		19,946		(541,151)	1,384
Beginning balance (in shares) at Dec. 31, 2020	164,244,893
Beginning balance at Dec. 31, 2020	$ 1,681,015
Ending balance (in shares) at Sep. 30, 2021	0
Ending balance at Sep. 30, 2021	$ 0
Beginning balance (in shares) at Dec. 31, 2020	137,662,698		137,663,000
Beginning balance at Dec. 31, 2020	$ (503,672)		$ 14		9,877		(515,989)	2,426
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(370,344)
Other comprehensive income (loss)	$ (2,196)
Ending balance (in shares) at Sep. 30, 2021	628,133,782		628,134,000
Ending balance at Sep. 30, 2021	$ 1,937,204		$ 63		2,823,244		(886,333)	230
Beginning balance (in shares) at Mar. 31, 2021	165,665,000
Beginning balance at Mar. 31, 2021	$ 1,736,152
Redeemable Preferred Stock
Issuance of preferred stock (in shares)	2,067,000
Issuance of preferred stock	$ 79,807
Conversion of preferred stock to common stock (in shares)	(167,732,000)
Conversion of preferred stock to common stock	$ (1,815,959)
Ending balance (in shares) at Jun. 30, 2021	0
Ending balance at Jun. 30, 2021	$ 0
Beginning balance (in shares) at Mar. 31, 2021			142,324,000
Beginning balance at Mar. 31, 2021	(519,807)		$ 14		19,946		(541,151)	1,384
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(44,518)						(44,518)
Conversion of preferred stock to common stock (in shares)			427,897,000
Conversion of preferred stock to common stock	1,815,959		$ 43		1,815,916
Issuance and sale of common stock (in shares)			4,120,000	51,350,000
Issuance and sale of common stock	4,723	$ 880,642	$ 1	$ 5	4,722	$ 880,637
Share-based compensation	13,878				13,878
Other comprehensive income (loss)	(851)							(851)
Ending balance (in shares) at Jun. 30, 2021			625,691,000
Ending balance at Jun. 30, 2021	$ 2,150,026		$ 63		2,735,099		(585,669)	533
Ending balance (in shares) at Sep. 30, 2021	0
Ending balance at Sep. 30, 2021	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(300,664)						(300,664)
Issuance and sale of common stock (in shares)			4,965,000
Issuance and sale of common stock	75,965				75,965
Return of common stock from escrow settlement (in shares)			(2,522,000)
Return of common stock from escrow settlement	(12,000)				(12,000)
Share-based compensation	24,180				24,180
Other comprehensive income (loss)	$ (303)							(303)
Ending balance (in shares) at Sep. 30, 2021	628,133,782		628,134,000
Ending balance at Sep. 30, 2021	$ 1,937,204		$ 63		$ 2,823,244		$ (886,333)	$ 230

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (370,344)	$ (84,610)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	25,981	5,550
Share-based compensation	43,234	3,722
Deferred income taxes	(17,946)	0
Unrealized gain on equity securities	(109,012)	0
Other, net	14,555	1,022
Changes in assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	(18,683)	27,508
Other assets	(86,836)	(24,980)
Medical cost payable	342,531	35,458
Risk adjustment payable	359,257	68,186
Accounts payable and other liabilities	53,853	(22,015)
Unearned revenue	(3,476)	1,498
Net cash provided by operating activities	233,114	11,339
Cash flows from investing activities:
Purchases of investments	(736,838)	(702,672)
Proceeds from sales, paydown, and maturities of investments	536,110	349,113
Purchases of property and equipment	(20,682)	(1,181)
Business acquisitions, net of cash acquired	(431,718)	(174,090)
Net cash used in investing activities	(653,128)	(528,830)
Cash flows from financing activities:
Proceeds from issuance of preferred stock	0	686,840
Proceeds from issuance of common stock	10,581	874
Proceeds from short-term borrowings	200,000	0
Repayments of short-term borrowings	(200,000)	0
Payments for debt issuance costs	(3,391)	0
Proceeds from IPO	887,328	0
Payments for IPO offering costs	(6,686)	0
Net cash provided by financing activities	887,832	687,714
Net increase in cash and cash equivalents	467,818	170,223
Cash and cash equivalents – beginning of year	488,371	522,910
Cash and cash equivalents – end of period	956,189	693,133
Supplemental disclosures of cash flow information:
Changes in unrealized (loss) gain on available-for-sale securities in OCI	(2,196)	2,258
Cash paid for interest	3,865	0
Supplemental schedule of non-cash activities:
Redeemable convertible preferred stock issued for acquisitions	134,944	80,000
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	$ 1,815,916	$ 0

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION Organization: Bright Health Group, Inc. and subsidiaries (collectively, “Bright Health,” “we,” “our,” “us,” or the “Company”) was founded in 2015 to transform healthcare. Our mission of Making Healthcare Right. Together. is built upon the belief that by connecting and aligning the local resources in healthcare delivery with the financing of care, we can drive a superior consumer experience, reduce systemic waste, lower costs, and optimize clinical outcomes. Stock Split: On June 2, 2021, we effected a stock split of the Company’s common stock on a 1-for-3 basis (the “Stock Split”). In connection with the Stock Split, the conversion rate for the Company’s preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Stock Split. Accordingly, all common stock share and per share amounts for all periods presented in these financial statements have been retroactively adjusted to reflect this Stock Split. Initial Public Offering: On June 28, 2021, we completed our initial public offering (“IPO”) in which we issued and sold 51,350,000 shares of common stock, par value $0.0001 per share, at an offering price of $18.00 per share. We received net proceeds of $887.3 million from the sale of our common stock, after deducting underwriting discounts and commissions of $37.0 million. We used a portion of the net proceeds from our IPO to repay in full our outstanding borrowings under our revolving credit facility, as well as to fund the acquisition of Centrum Medical Holdings, LLC (“Centrum”). Refer to Note 2, Business Combinations , and Note 7, Short-Term Borrowings for more information. The Company’s Common Stock is traded on the New York Stock Exchange (the “NYSE”) under the symbol “BHG”. We incurred $6.7 million of deferred offering costs consisting primarily of accounting, legal and other fees related to our IPO, which were recorded against IPO proceeds within additional paid-in capital upon closing of our IPO. Conversion of Preferred Stock into Common Stock: On June 28, 2021, the Company issued 427,897,381 shares of common stock upon conversion (the “Conversion”) of all outstanding shares of its Series A Convertible Preferred Stock, par value $0.0001 per share, Series B Convertible Preferred Stock, par value $0.0001 per share, Series C Convertible Preferred Stock, par value $0.0001 per share, Series D Convertible Preferred Stock, par value $0.0001 per share, and Series E Convertible Preferred Stock, par value $0.0001 per share (collectively, the “Preferred Stock”), pursuant to its eighth amended and restated certificate of incorporation. Conversion of the preferred stock into shares of common stock occurred automatically immediately prior to the closing of our IPO. Basis of Presentation: The condensed consolidated financial statements include the accounts of Bright Health Group, Inc. and all subsidiaries and controlled companies. All intercompany balances and transactions are eliminated upon consolidation. The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our audited consolidated financial statements, unless the information contained in those disclosures materially changed or is required by GAAP. As such, the condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2020 included in the prospectus dated June 23, 2021 (File No.333-256286) (the “Prospectus”), as filed with the United States Securities and Exchange Commission (“SEC”) pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended. The accompanying condensed consolidated financial statements include all normal recurring adjustments necessary for fair presentation of the interim financial statements. Use of Estimates: The preparation of our condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Our most significant estimates include medical costs payable, risk adjustment revenue and associated payables and receivables, valuation and impairment of goodwill and other intangible assets, valuation and impairment of investments and estimates of share-based compensation. Actual results could differ from these estimate s. For the three months ended September 30, 2021, we recognized a change in estimate for risk adjustment of $134.0 million as a result of updated data inputs used to calculate Individual and Family Plan (“IFP”) members’ expected full year risk scores, which resulted in an increase in risk adjustment payable in the Condensed Consolidated Balance Sheets and a reduction in premium revenue in the Condensed Consolidated Statements of Income (Loss). Operating Costs: Our operating costs, by functional classification for the three and nine months ended September 30, 2021 and 2020, are as follows (in thousands) : Three Months Ended Nine Months Ended 2021 2020 2021 2020 Compensation and fringe benefits $ 100,062 $ 35,588 $ 234,467 $ 92,589 Professional fees 61,483 20,745 143,248 53,381 Marketing and selling expense 69,443 15,941 183,636 39,056 Other operating expenses 78,802 25,105 217,739 75,624 Total operating costs $ 309,790 $ 97,379 $ 779,090 $ 260,650 Recently Issued and Adopted Accounting Pronouncements: There were no accounting pronouncements that were recently issued and not yet adopted or adopted since our audited consolidated financial statements that had, or are expected to have, a material impact on our consolidated financial position, results of operations, or cash flows.

BUSINESS COMBINATIONS

BUSINESS COMBINATIONS	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
BUSINESS COMBINATIONS	BUSINESS COMBINATIONS Centrum Acquisition: On July 1, 2021, we acquired 75% of the outstanding equity interests of Centrum for cash consideration of $222.4 million and $75.0 million of common stock, for total purchase consideration of $296.2 million, net of $1.2 million of cash acquired. Centrum is a value-based primary care focused, multi-specialty medical group based in Florida. Centrum operates 17 health centers in Florida, serving Commercial, Medicare, and Medicaid consumers across multiple payors, with secured expansion locations in Texas and North Carolina. Centrum is included in our NeueHealth reportable segment. Transaction costs of $1.0 million incurred in connection with the acquisition are included in operating costs in the Condensed Consolidated Statements of Income (Loss) for the nine months ended September 30, 2021. The total preliminary purchase consideration for the Centrum acquisition is allocated to tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the acquisition date. The excess of the purchase price over the net assets acquired is recorded as goodwill, which is predominantly attributable to the incremental financial benefits achievable through Bright Health Group’s integrated care delivery model, whereby Bright HealthCare members are cared for under value-based arrangements with Centrum. This model brings together the financing, distribution, and delivery of high-quality healthcare and provides the opportunity to enhance overall margin potential for the Company. The following table discloses the preliminary estimated fair values of assets and liabilities acquired by the Company in the Centrum acquisition (in thousands) : Accounts receivable $ 1,874 Prepaids and other current assets 627 Property and equipment 2,557 Intangible assets 102,370 Other assets 8,917 Total assets 116,345 Medical payables 19 Accounts payable 359 Other current liabilities 861 Other liabilities 11,636 Total liabilities 12,875 Net identified assets acquired 103,470 Goodwill 277,831 Redeemable noncontrolling interest (85,075) Total purchase consideration $ 296,226 The preliminary fair values of acquired assets and liabilities assumed represent management’s estimate of fair value and are subject to change if additional information, such as post-close working capital adjustments, becomes available. The Company is in process of identifying any additional intangible assets that would reduce the goodwill recognized. The fair values of certain assets and liabilities have changed from previous disclosure. We obtained additional information to estimate the fair value of the right-of-use lease asset and liability included within other assets and other liabilities. We also updated the fair value of intangible assets based on the methodologies described below. Our preliminary estimate of intangible assets related to the Centrum acquisition consists of trade names with a 15-year useful life, customer relationships with 2- to 15-year useful lives, and a reacquired contract between Bright HealthCare and Centrum with a useful life of 4.5 years. The value of the trade name was determined using the relief of royalty method and the excess earnings method was used to value the customer relationships; both methods are considered Level 3 fair value measurements. The fair value of noncontrolling interest was determined using a market approach and included a discount to account for the lack of marketability of the noncontrolling interest. The acquisition of Centrum would not have had a material impact on our revenue or net loss had it been included in the consolidated results of the Company for the nine months ended September 30, 2021 or the three and nine months ended September 30, 2020. Central Health Plan Acquisition: On April 1, 2021, we acquired all of the outstanding shares of Central Health Plan of California, Inc. (“CHP”) for cash consideration of $276.0 million and $79.8 million in Series E preferred stock, for total purchase consideration of $271.7 million, net of $84.1 million of cash acquired. CHP is an insurance provider of Medicare Advantage (“MA”) HMO services. CHP is included in our Bright HealthCare reportable segment. Transaction costs of $0.2 million incurred in connection with the acquisition are included in operating costs in the Condensed Consolidated Statements of Income (Loss) for the nine months ended September 30, 2021, out of $1.4 million of total transaction cost s we have incurred. The total preliminary purchase consideration for the CHP acquisition is allocated to tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the acquisition date. The excess of the purchase price over the net assets acquired is recorded as goodwill. The goodwill for CHP is attributable to synergies from leveraging CHP’s clinical model and California consumer expertise to continue to expand our MA business in the California market. The goodwill is not deductible for tax purposes. The following table discloses the preliminary estimated fair values of assets and liabilities acquired by the Company in the CHP acquisition (in thousands) : Accounts receivable $ 16,361 Short-term investments 19,041 Prepaids and other current assets 25,520 Property and equipment 370 Intangible assets 102,000 Total assets 163,292 Medical costs payable 79,450 Accounts payable 2,371 Other current liabilities 17,212 Other liabilities 28,622 Total liabilities 127,655 Net identified assets acquired 35,637 Goodwill 236,037 Total purchase consideration $ 271,674 The preliminary fair values of acquired assets and liabilities assumed represent management’s estimate of fair value and are subject to change if additional information, such as post-close working capital adjustments, becomes available. Our preliminary estimate of intangible assets related to the CHP acquisition consists of customer relationships with a 10-year useful life, trade names with a 15-year useful life and the provider network with a 7-year useful life. The value of the trade name was determined using the relief from royalty method and the excess earnings method was used to value the customer relationships; both methods are considered Level 3 fair value measurements. The following pro forma financial information presents our revenue and net loss as if CHP had been included in the consolidated results of the Company for the nine months ended September 30, 2021 and the three and nine months ended September 30, 2020 (in thousands) : Pro Forma Consolidated Statements of Income (Loss) (Unaudited) Three Months Ended Nine Months Ended September 30, 2020 2021 2020 Revenue $ 502,378 $ 3,195,925 $ 1,263,016 Net Loss (49,157) (358,935) (70,971) True Health New Mexico and Zipnosis Acquisitions: On March 31, 2021 we acquired all of the outstanding equity interests of True Health New Mexico, Inc. (“THNM”) for cash consideration of $27.5 million, net of cash acquired of $24.1 million, for total purchase consideration of $3.4 million. THNM is a physician-led health insurance company offering policies available through the commercial market for individual on- and off-exchange and employer-sponsored health coverage. THNM is included in our Bright HealthCare reportable segment. In addition, on March 31, 2021, we acquired Zipnosis, Inc. (“Zipnosis”), which is a telehealth platform that offers virtual care to health systems around the U.S., for aggregate consideration of $73.0 million, including $55.1 million in Series E preferred stock and adjusted for $0.5 million of tangible net equity adjustments. We acquired $3.2 million of cash as part of the Zipnosis acquisition, for net total purchase consideration of $69.8 million. Zipnosis is included in our NeueHealth reportable segment. Transaction costs of $0.5 million incurred in connection with these acquisitions are included in operating costs in the Condensed Consolidated Statements of Income (Loss) for the nine months ended September 30, 2021. The total preliminary purchase consideration for the THNM and Zipnosis acquisitions is allocated to tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the acquisition date. The excess of the purchase price over the net assets acquired is recorded as goodwill. The goodwill for THNM is attributable to synergies from leveraging THNM’s strong local clinical model of care and the ability to enter into a new state of strategic interest for future growth and expansion. The goodwill from the Zipnosis acquisition is attributable to benefits from the ability to enhance our proprietary technology platform, DocSquad, and Zipnosis’ attractive virtual care capabilities to enhance Bright Health’s consumer and provider connectivity. The goodwill from the THNM and Zipnosis acquisitions is not deductible for tax purposes. The following table discloses the preliminary estimated fair values of assets and liabilities acquired by the Company in the THNM and Zipnosis acquisitions (in thousands) : THNM Zipnosis Accounts receivable $ 714 $ 1,062 Short-term investments 4,677 — Prepaids and other current assets 8,337 141 Property and equipment — 232 Intangible assets 7,300 8,970 Long-term investments 13,081 — Other non-current assets 1,324 766 Total assets 35,433 11,171 Medical costs payable 13,268 — Accounts payable 14,663 136 Unearned revenue 3,645 120 Other current liabilities 2,682 665 Other liabilities 2,499 2,730 Total liabilities 36,757 3,651 Net identified assets acquired (1,324) 7,520 Goodwill 4,739 62,277 Total purchase consideration $ 3,415 $ 69,797 The preliminary fair values of acquired assets and liabilities assumed represent management’s estimate of fair value and are subject to change if additional information, such as post-close working capital adjustments, becomes available. Our preliminary estimate of intangible assets related to the THNM acquisition consists of customer relationships with 10-to 14-year useful lives, trade names with a 15-year useful life and the provider network with a 7-year useful life. For the Zipnosis acquisition, our preliminary estimate of intangible assets consists of customer relationships with a 15-year useful life, trade names with a 5-year useful life and developed technology with a 7-year useful life. For these acquisitions the value of the trade names and developed technology was determined using the relief from royalty method and the excess earnings method was used to value the customer relationships; both methods are considered Level 3 fair value measurements. The following pro forma financial information presents our revenue and net loss as if THNM and Zipnosis had been included in the consolidated results of the Company for the nine months ended September 30, 2021 and three and nine months ended September 30, 2020 (in thousands) : Pro Forma Consolidated Statements of Income (Loss) (Unaudited) Three Months Ended Nine Months Ended September 30, 2020 2021 2020 Revenue 384,797 $ 3,114,954 943,286 Net Loss (57,035) $ (372,315) (85,988) PMA Acquisition: On December 31, 2020, we acquired a 62% controlling interest in Premier Medical Associates of Florida, LLC (“PMA”) in exchange for $74.2 million. PMA provides care services to Medicare and Medicaid patients in Florida through a network of primary care providers and population health-focused specialists. The acquisition of PMA is expected to enhance our clinical capabilities to better serve enrollees as part of our Florida market expansion. The total purchase consideration for the PMA acquisition was allocated to tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the acquisition date. The excess of the purchase price over the net assets acquired was recorded as goodwill. The purchase price allocation is preliminary and subject to change, including the valuation of property, equipment and capitalized software and intangible assets, among other items. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. BND Acquisition: On April 30, 2020, we acquired all of the outstanding shares of Universal Care, Inc. (d.b.a. Brand New Day) (“BND”). BND is a leader in providing healthcare services in California and serves Medicare eligible seniors and special needs populations through their extensive network of primary care providers and specialists. BND combines analytics and evidence-based clinical programs with aligned provider relationships to provide high quality, affordable care for complex and vulnerable populations. The total consideration included $206.9 million in cash and $80.0 million in Bright Health Series D preferred stock. We have since applied indemnity escrow adjustments of $44.0 million to the acquisition price, bringing total consideration to $210.1 million, net of cash acquired of $32.8 million. Transaction costs of $3.8 million incurred in connection with the acquisition are included in operating costs in the Consolidated Statements of Income (Loss) for the year ended December 31, 2020. If BND had been included in the consolidated results of the Company for the nine months ended September 30, 2020, our pro forma revenue would have been $1.0 billion, and our pro forma net loss would have been $(100.9) million. The total purchase consideration for the BND acquisition was allocated to tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the acquisition date. The excess of the purchase price over the net assets acquired was recorded as goodwill. The goodwill is attributable to synergies from leveraging BND’s strong clinical model of care to drive growth in our MA business outside of California. The goodwill from the BND acquisition is not deductible for tax purposes. The following table discloses the preliminary estimated fair values of assets and liabilities acquired by the Company in the BND acquisition, as well as measurement adjustments made in the nine months ended September 30, 2021 to the amounts initially recorded in 2020 (in thousands) : Amount Recognized as of Measurement Amounts Recognized as of Accounts receivable $ 74,128 $ — $ 74,128 Prepaid and other currents assets 30,583 — 30,583 Property and equipment 4,375 — 4,375 Intangible assets 72,600 1,900 74,500 Other non-current assets 2,906 — 2,906 Total assets 184,592 1,900 186,492 Medical costs payable 119,408 — 119,408 Other current liabilities 51,744 174 51,918 Other liabilities 1,236 108 1,344 Total liabilities 172,388 282 172,670 Net identified assets acquired 12,204 1,618 13,822 Goodwill 197,886 (1,618) 196,268 Total purchase consideration $ 210,090 $ — $ 210,090 The measurement period adjustments above primarily resulted from completing valuations for certain intangible assets. The related impact to net earnings that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the consolidated financial statements. We recognized intangible assets related to the BND acquisition, which consist of $25.6 million for the BND trade name with an estimated useful life of 15 years, customer relationships valued at $46.9 million with a 12-year useful life, and $2.0 million of other intangibles related to the provider network with a 10-year useful life. The value of the trade name was determined using the relief from royalty method and the excess earnings method was used to value the customer relationships; both methods are considered Level 3 fair value measurements.

INVESTMENTS

INVESTMENTS	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS	INVESTMENTS Fixed Maturity Securities Available-for-sale securities are reported at fair value as of September 30, 2021 and December 31, 2020. Held-to-maturity securities are reported at amortized cost as of September 30, 2021 and December 31, 2020. The following is a summary of our investment securities as of September 30, 2021 and December 31, 2020 (in thousands) : September 30, 2021 Amortized Gross Gross Carrying Cash equivalents $ 271,984 $ 1 $ (1) $ 271,984 Available for sale: U.S. government and agency obligations 501,343 283 (376) 501,250 Corporate obligations 290,917 384 (106) 291,195 State and municipal obligations 15,437 51 (3) 15,485 Commercial paper 5,160 5 — 5,165 Certificates of deposit 26,809 — — 26,809 Mortgage-backed securities 2,533 — — 2,533 Other 12,876 1 (8) 12,869 Total available-for-sale securities 855,075 724 (493) 855,306 Held to maturity: U.S. government and agency obligations 7,745 — — 7,745 Certificates of deposit 1,447 — — 1,447 Total held-to-maturity securities 9,192 — — 9,192 Total investments $ 1,136,251 $ 725 $ (494) $ 1,136,482 December 31, 2020 Amortized Gross Gross Carrying Cash equivalents $ 153,743 $ — $ (3) $ 153,740 Available for sale: U.S. government and agency obligations 291,834 1,246 (1) 293,079 Corporate obligations 280,557 1,104 (30) 281,631 State and municipal obligations 18,459 107 — 18,566 Commercial paper 14,990 1 — 14,991 Certificates of deposit 53,504 2 (1) 53,505 Other 5,534 2 — 5,536 Total available-for-sale securities 664,878 2,462 (32) 667,308 Held to maturity: U.S. government and agency obligations 6,677 — — 6,677 Certificates of deposit 1,119 — — 1,119 Total held-to-maturity securities 7,796 — — 7,796 Total investments $ 826,417 $ 2,462 $ (35) $ 828,844 The fair value of available-for-sale investments, including those that are cash equivalents, with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position at September 30, 2021 and December 31, 2020 were as follows (in thousands) : September 30, 2021 Less Than 12 Months 12 Months or Greater Total Description of Investments Fair Unrealized Fair Unrealized Fair Unrealized Cash equivalents $ 9,643 $ (1) $ — $ — $ 9,643 $ (1) U.S. government and agency obligations 347,735 (376) — — 347,735 (376) Corporate obligations 137,456 (106) — — 137,456 (106) State and municipal obligations 2,812 (3) — — 2,812 (3) Other 10,950 (8) — — 10,950 (8) Total bonds $ 508,596 $ (494) $ — $ — $ 508,596 $ (494) December 31, 2020 Less Than 12 Months 12 Months or Greater Total Description of Investments Fair Unrealized Fair Unrealized Fair Unrealized Cash equivalents $ 25,007 $ (3) $ — $ — $ 25,007 $ (3) U.S. government and agency obligations 12,507 (1) — — 12,507 (1) Corporate obligations 121,006 (30) — — 121,006 (30) Commercial paper 999 — — — 999 — Certificates of deposit 14,003 (1) — — 14,003 (1) Total bonds $ 173,522 $ (35) $ — $ — $ 173,522 $ (35) As of September 30, 2021, we had 744 investment positions out of 1,859 that were in an unrealized loss position. As of December 31, 2020, we had 117 investment positions out of 1,917 that were in an unrealized loss position. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. At each reporting period, we evaluate securities for impairment when the fair value of the investment is less than its amortized cost. We evaluated the underlying credit quality and credit ratings of the issuers, noting no significant deterioration since purchase. As of September 30, 2021, we did not have the intent to sell any of the securities in an unrealized loss position. Therefore, we believe these losses to be temporary. As of September 30, 2021, the maturity of available-for-sale securities, by contractual maturity, reflected at amortized cost and fair value were as follows (in thousands) : Amortized Fair Due in one year or less $ 203,284 $ 203,614 Due after one year through five years 651,705 651,606 Due after five years through 10 years 86 86 Due after 10 years — — Total debt securities $ 855,075 $ 855,306 Investment income in the Condensed Consolidated Statements of Income (Loss) for the nine months ended September 30, 2021 and 2020, was $3.5 million, and $7.1 million, respectively, related to our fixed maturity securities. Realized gains (losses) from our fixed maturity securities of $0.4 million and $0.1 million are included within total investment income, and reclassified out of accumulated other comprehensive income, for the nine months ended September 30, 2021 and 2020, respectively. Equity Securities

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Basis of fair value measurement: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets or quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability. Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). Certain assets and liabilities are measured at fair value in the condensed consolidated financial statements or have fair values disclosed in the notes to the condensed consolidated financial statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, except for the equity securiti es, see note 5 of notes to the audited consolidated financial statements included in our Prospectus filed with the SEC. Equity Securities — The fair value of the equity securities was determined based on the quoted market price of the underlying securities in an active market. The following tables set forth our fair value measurements as of September 30, 2021 and December 31, 2020, for assets measured at fair value on a recurring basis (in thousands): September 30, 2021 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 209,727 $ 35,507 $ — $ 245,234 Fixed maturity securities, available for sale: U.S. government and agency obligations 358,202 143,048 — 501,250 Corporate obligations 2,234 288,961 — 291,195 State and municipal obligations — 15,485 — 15,485 Commercial paper — 5,165 — 5,165 Certificates of deposit 18,738 8,071 — 26,809 Mortgage-backed securities 2,533 — — 2,533 Other — 12,869 — 12,869 Total fixed maturity securities, available for sale: 381,707 473,599 — 855,306 Equity securities 149,144 — — 149,144 Total assets at fair value $ 740,578 $ 509,106 $ — $ 1,249,684 Liabilities Contingent consideration $ — $ — $ 7,079 $ 7,079 December 31, 2020 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 149,499 $ 4,019 $ — $ 153,518 Fixed maturity securities, available for sale: U.S. government and agency obligations 197,886 95,193 — 293,079 Corporate obligations — 281,631 — 281,631 State and municipal obligations — 18,566 — 18,566 Commercial paper — 14,991 — 14,991 Certificates of deposit — 53,505 — 53,505 Other — 5,536 — 5,536 Total assets at fair value $ 347,385 $ 473,441 $ — $ 820,826 Liabilities Contingent consideration $ — $ — $ 5,716 $ 5,716 The following tables set forth the Company’s fair value measurements as of September 30, 2021 and December 31, 2020, for certain financial instruments not measured at fair value on a recurring basis (in thousands) : September 30, 2021 Level 1 Level 2 Level 3 Total Cash equivalents, held to maturity $ 26,750 $ — $ — $ 26,750 Fixed maturity securities, held to maturity: U.S. government and agency obligations 7,768 — — 7,768 Certificates of deposit 1,447 — — 1,447 Total held to maturity $ 35,965 $ — $ — $ 35,965 December 31, 2020 Level 1 Level 2 Level 3 Total Cash equivalents, held to maturity $ 222 $ — $ — $ 222 Fixed maturity securities, held to maturity: U.S. government and agency obligations 6,732 — — 6,732 Certificates of deposit — 1,119 — 1,119 Total held to maturity $ 6,954 $ 1,119 $ — $ 8,073 There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The contingent consideration liability related to the acquisition of AssociatesMD Medical Group, Inc. is measured using Level 3 inputs based on a formulaic multiple of forecasted 2023 EBITDA per the terms of the purchase agreement discounted back to net present value. The following table presents the changes in fair value of the contingent consideration liability for the nine months ended September 30, 2021 and year ended December 31, 2020 (in thousands) : 2021 2020 Balance at beginning of period $ 5,716 $ 5,716 Change in fair value of contingent consideration 1,363 — Balance at end of period $ 7,079 $ 5,716 The carrying amounts reported on the Condensed Consolidated Balance Sheets for other current financial assets and liabilities approximate fair value due to their short-term nature. These assets and liabilities are not included in the tables above.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Changes in the carrying value of goodwill by reportable segment were as follows (in thousands) : Bright HealthCare NeueHealth Gross Carrying Cumulative Gross Carrying Cumulative Balance at December 31, 2020 $ 197,886 $ — $ 65,149 $ — Acquisitions 240,776 340,108 Purchase adjustments (1,618) — — — Balance at September 30, 2021 $ 437,044 $ — $ 405,257 $ — The gross carrying value and accumulated amortization for definite-lived intangible assets were as follows (in thousands) : September 30, 2021 December 31, 2020 Gross Carrying Accumulated Amortization Gross Carrying Accumulated Amortization Customer relationships $ 209,321 $ 19,257 $ 117,451 $ 3,664 Trade names 99,231 5,057 38,161 1,604 Reacquired contract 59,000 3,278 — — Developed technology 6,200 443 — — Other 6,400 598 2,000 133 Total $ 380,152 $ 28,633 $ 157,612 $ 5,401 The acquisition date fair values and weighted-average useful lives assigned to definite-lived intangible assets acquired during the nine months ended September 30, 2021 were as follows (in thousands) : Fair Value Weighted-Average Customer relationships $ 90,670 16.0 Trade names 60,370 14.9 Reacquired contract 59,000 4.5 Developed technology 6,200 7.0 Other 4,400 7.0 Total $ 220,640 9.8 Amortization expense relating to intangible assets for the three months ended September 30, 2021 and 2020 was $13.3 million and $1.8 million, respectively, and amortization expense for the nine months ended September 30, 2021 and 2020 was $23.2 million and $3.6 million, respectively. Estimated amortization expense relating to intangible assets for the remainder of 2021 and for each of the next five full years ending December 31 is as follows (in thousands) : 2021 (October-December) $ 10,513 2022 42,050 2023 42,029 2024 41,890 2025 41,890 2026 26,323

MEDICAL COSTS PAYABLE

MEDICAL COSTS PAYABLE	9 Months Ended
	Sep. 30, 2021
Insurance [Abstract]
MEDICAL COSTS PAYABLE	MEDICAL COSTS PAYABLE The following table shows the components of the change in medical costs payable for the nine months ended September 30 (in thousands) : 2021 2020 Medical costs payable - January 1 $ 249,777 $ 44,804 Incurred related to: Current year 2,647,719 685,637 Prior year 1,726 (9,297) Total incurred 2,649,445 676,340 Paid related to: Current year 2,074,602 610,161 Prior year 232,312 29,974 Total paid 2,306,914 640,135 Acquired claims liabilities 92,737 118,662 Medical costs payable - September 30 $ 685,045 $ 199,671 Medical costs payable attributable to prior years increased by $1.7 million and decreased by $9.3 million for the nine months ended September 30, 2021 and 2020, respectively. Medical costs payable estimates are adjusted as additional information becomes known regarding claims; there were no significant changes to estimation methodologies during the periods. The table below details the components making up the medical costs payable as of September 30 (in thousands) : 2021 2020 Claims unpaid $ 42,488 $ 25,961 Provider incentive payable 69,274 10,391 Claims adjustment expense liability 12,413 2,572 Incurred but not reported 560,870 160,747 Total medical costs payable $ 685,045 $ 199,671 Medical costs payable are primarily related to the current year. The Company has recorded claims adjustment expense as a component of operating costs in the Condensed Consolidated Statements of Income (Loss).

SHORT-TERM BORROWINGS

SHORT-TERM BORROWINGS	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
SHORT-TERM BORROWINGS	SHORT-TERM BORROWINGSOn March 1, 2021, we entered into a $350.0 million revolving credit agreement with a syndicate of banks (the “Credit Agreement”). On August 2, 2021, the Credit Agreement was amended to change the definition of “Qualified IPO” by reducing the net proceeds required to be received by the Company from $1.0 billion to $850.0 million. In addition, prior to such amendment, the Credit Agreement contained a covenant that required the Company to maintain a total debt to capitalization ratio of (a) 0.25 to 1.00 prior to a Qualified IPO, and (b) 0.30 to 1.00 after a Qualified IPO. The Amendment changed this covenant by removing the increase in the ratio after a Qualified IPO such that the Company is now required to maintain a total debt to capitalization ratio of 0.25 to 1.00. On August 4, 2021, we elected to extend the maturity date of the Credit Agreement from February 28, 2022 to February 28, 2024. During the second quarter of 2021, we utilized a portion of the net IPO proceeds to repay the $200.0 million principal balance of indebtedness outstanding under our revolving credit agreement originally entered into on March 1, 2021 and the associated interest and other costs of $3.2 million. As of September 30, 2021, we have no borrowings outstanding under the Credit Agreement.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION 2016 Incentive Plan The Company adopted its 2016 Stock Incentive Plan (the “2016 Incentive Plan”) in March 2016. The 2016 Incentive Plan allowed for the Company to grant stock options, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”) to certain employees, consultants and non-employee directors. The 2016 Incentive Plan was initially adopted on March 25, 2016, and most recently amended in December 2020. Following the effectiveness of our 2021 Omnibus Plan (the “2021 Incentive Plan”), no further awards will be granted under the 2016 Incentive Plan. However, all outstanding awards granted under the 2016 Incentive Plan will continue to be governed by the existing terms of the 2016 Incentive Plan and the applicable award agreements. 2021 Incentive Plan The 2021 Incentive Plan was adopted by our Board of Directors on May 21, 2021 and approved by our stockholders on May 25, 2021 and June 5, 2021. The 2021 Incentive Plan allows the Company to grant stock options, RSAs, RSUs, stock appreciation rights, other equity based awards, and cash based incentive awards to certain employees, consultants and non-employee directors. There are 42.0 million shares of common stock authorized for issuance under the 2021 Incentive Plan. As of September 30, 2021, a total of 26.8 million shares of common stock were available for future issuance under the 2021 Incentive Plan. Share-Based Compensation Expense We recognized share-based compensation expense of $43.2 million and $3.7 million for the nine months ended September 30, 2021 and 2020, respectively, which is included in operating costs in the Condensed Consolidated Statements of Income (Loss). Stock Options The Board of Directors or the Compensation Committee of the Board of Directors determines the exercise price, vesting periods and expiration date at the time of the grant. Stock options granted prior to the third quarter of 2021 generally vest 25% at one year from the grant date, then ratably over the next 36 months with continuous employee service. Stock options granted after the beginning of the third quarter of 2021 generally vest ratably over three years. Option grants generally expire 10 years from the date of grant. The calculated value of each option award is estimated on the date of grant using a Black-Scholes option valuation model that used the following weighted-average assumptions for options granted during the nine months ended September 30, 2021: 2021 Risk-free interest rate 0.8 % Expected volatility 33.3 % Expected dividend rate 0.0 % Forfeiture rate 14.5 % Expected life in years 6.1 Risk-free interest rates are based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on the historical volatility of our publicly traded industry peers. We use historical data to estimate option forfeitures within the valuation model. The expected lives of options granted represent the period of time that the awards granted are expected to be outstanding based on historical exercise patterns. The activity for the stock options for the nine months ended September 30, 2021 is as follows (in thousands, except exercise price and contractual life) : Shares Weighted-Average Weighted-Average Aggregate Outstanding at January 1, 2021 63,925 $ 1.47 8.7 $ 53,573 Granted 20,447 2.58 Exercised (9,373) 1.09 Forfeited (4,709) 1.75 Expired (11) 1.09 Outstanding at September 30, 2021 70,279 $ 1.83 8.5 $ 445,246 The weighted-average grant date fair value of stock options granted during the nine months ended September 30, 2021 was $10.86 per share. At September 30, 2021, there was $150.7 million of unrecognized compensation expense related to stock options that is expected to be recognized over a weighted-average period of 3.4 years. Restricted Stock Units RSUs represent the right to receive shares of our common stock at a specified date in the future and generally vest over a three-year period. The fair value of RSUs is determined based on the closing market price of our common stock on the date of grant. The following table summarizes RSU award activity for the nine months ended September 30, 2021 ( in thousands, except weighted average grant date fair value ) : RSU Number of RSUs Weighted Average Grant Date Fair Value Unvested RSUs at December 31, 2020 — $ — RSUs granted 364 9.11 RSUs canceled (19) 9.01 Unvested RSUs at September 30, 2021 345 $ 9.11 We recognized share-based compensation expense related to RSUs of $0.2 million for the three and nine months ended September 30, 2021, which is included in operating costs in the Condensed Consolidated Statements of Income (Loss). As of September 30, 2021, there was $2.5 million of unrecognized compensation expense related to the RSU grants, which is expected to be recognized over a weighted-average period of 2.7 years. Performance-based Restricted Stock Units (“PSUs”) In connection with our IPO, our Board of Directors approved the grant of PSUs to members of our executive leadership team. The grant encompasses a total of 14.7 million PSUs, separated into four equal tranches, each of which are eligible to vest based on the achievement of predetermined stock price goals and a minimum service period of 3 years. This grant is intended to retain and incentivize our executive leadership to lead the Company to sustained, long-term financial and operational performance. The fair value of the PSUs is determined using a Monte-Carlo simulation. The following table summarizes PSU award activity for the nine months ended September 30, 2021 (in thousands, except weighted average grant date fair value) : PSU Number of PSUs Weighted Average Grant Date Fair Value Unvested PSUs at December 31, 2020 — $ — PSUs granted 14,700 9.30 PSUs canceled — — Unvested PSUs at September 30, 2021 14,700 $ 9.30

NET LOSS PER SHARE

NET LOSS PER SHARE	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
NET LOSS PER SHARE	NET LOSS PER SHARE The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30 (in thousands, except for per share amounts) : Three Months Ended September 30, Nine Months Ended 2021 2020 2021 2020 Net loss attributable to Bright Health Group, Inc. common shareholders $ (300,664) $ (59,256) $ (370,344) $ (84,610) Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted 630,378 136,337 312,294 135,926 Net loss per share attributable to common stockholders, basic and diluted $ (0.48) $ (0.43) $ (1.19) $ (0.62) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive effect for the nine months ended September 30 (in thousands) : Nine Months Ended 2021 2020 Redeemable convertible preferred stock (as converted to common stock) — 411,238 Stock options to purchase common stock 70,279 58,224 Total 70,279 469,462

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal proceedings: In the normal course of business, we could be involved in various legal proceedings such as, but not limited to, the following: lawsuits alleging negligence in care or general liability, violation of regulatory bodies’ rules and regulations, or violation of federal and/or state laws. At September 30, 2021 and December 31, 2020, there were no material known contingent liabilities.

SEGMENT AND GEOGRAPHICAL INFORM

SEGMENT AND GEOGRAPHICAL INFORMATION	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHICAL INFORMATION	SEGMENTS AND GEOGRAPHIC INFORMATION Our two reportable segments are Bright HealthCare and NeueHealth. The following tables present the reportable segment financial information for the three and nine months ended September 30, 2021 and 2020 (in thousands) : Three Months Ended September 30, 2021 Bright NeueHealth Eliminations Consolidated Premium revenue $ 994,586 $ 25,647 $ — $ 1,020,233 Service revenue (61) 11,140 — 11,079 Investment income 1,087 46,258 — 47,345 Total unaffiliated revenue 995,612 83,045 — 1,078,657 Affiliated revenue — 139,759 (139,759) — Total segment revenue 995,612 222,804 (139,759) 1,078,657 Operating income (loss) (303,271) 6,990 — (296,281) Depreciation and amortization $ 4,584 $ 9,621 $ — $ 14,205 Three Months Ended September 30, 2020 Bright NeueHealth Eliminations Consolidated Premium revenue $ 343,472 $ 1,954 $ — $ 345,426 Service revenue — 4,920 — 4,920 Investment income 1,774 — — 1,774 Total unaffiliated revenue 345,246 6,874 — 352,120 Affiliated revenue — 2,727 (2,727) — Total segment revenue 345,246 9,601 (2,727) 352,120 Operating income (loss) (57,263) (1,993) — (59,256) Depreciation and amortization $ 2,274 $ 404 $ — $ 2,678 Nine Months Ended September 30, 2021 Bright NeueHealth Eliminations Consolidated Premium revenue $ 2,860,270 $ 62,680 $ — $ 2,922,950 Service revenue 29 31,573 — 31,602 Investment income 3,491 109,012 — 112,503 Total unaffiliated revenue 2,863,790 203,265 — 3,067,055 Affiliated revenue — 182,392 (182,392) — Total segment revenue 2,863,790 385,657 (182,392) 3,067,055 Operating income (loss) (443,450) 65,291 — (378,159) Depreciation and amortization $ 11,524 $ 14,457 $ — $ 25,981 Nine Months Ended September 30, 2020 Bright NeueHealth Eliminations Consolidated Premium revenue $ 821,185 $ 5,950 $ — $ 827,135 Service revenue — 13,344 — 13,344 Investment income 7,063 — — 7,063 Total unaffiliated revenue 828,248 19,294 — 847,542 Affiliated revenue — 8,176 (8,176) — Total segment revenue 828,248 27,470 (8,176) 847,542 Operating income (loss) (88,427) (5,345) — (93,772) Depreciation and amortization $ 4,131 $ 1,419 $ — $ 5,550 For all periods presented, all of our long-lived assets were located in the United States, and all revenues were earned in the United States. We do not include asset information by reportable segment in the reporting provided to the chief operating decision maker.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income tax expense (benefit) was an expense of $0.1 million and a benefit of $18.2 million for the three and nine months ended September 30, 2021, respectively. The impact from income taxes varies from the federal statutory rate of 21.0% due to changes in the valuation allowance for deferred tax assets and adjustments for permanent differences. For the three months ended September 30, 2021, the expense largely relates to amortization of originating goodwill from asset acquisitions. For the nine months ended September 30, 2021, the overall tax benefit is primarily due to the release of valuation allowance in connection with new deferred tax liabilities recorded on identifiable intangibles as part of business combination accounting for the BND, Zipnosis, THNM, and CHP stock acquisitions. The Centrum acquisition was treated as an asset acquisition, and accordingly, no deferred tax assets or liabilities were recorded as part of business-combination accounting.

REDEEMABLE NONCONTROLLING INTER

REDEEMABLE NONCONTROLLING INTEREST	9 Months Ended
	Sep. 30, 2021
Noncontrolling Interest [Abstract]
REDEEMABLE NONCONTROLLING INTEREST	REDEEMABLE NONCONTROLLING INTEREST As part of the Centrum acquisition on July 1, 2021, we entered into put/call agreements with respect to the equity interests in Centrum held by the controlling interest holder. The call options allow for the Company to purchase the 25% noncontrolling interest equity over time beginning on September 30, 2022, or under certain other accelerating events as defined in the agreement, solely at the Company’s discretion. The put options allow the noncontrolling interest holder the ability to cause the Company to purchase their noncontrolling equity interest on consistent terms with the call options. Based on the nature of the put option’s redemption features, which are outside the control of the Company, the noncontrolling interests are classified as redeemable in the accompanying Condensed Consolidated Balance Sheets at September 30, 2021. The put option redemption feature that is outside the control of the Company is settled based on EBITDA, which is an other than fair value settlement amount. As such, we will make a measurement adjustment when the put option redemption price exceeds the carrying amount as calculated under ASC 810, Consolidation . There was no redeemable noncontrolling interest during the three and nine months ended September 30, 2020. The following table provides details of our redeemable noncontrolling interest activity for the three and nine months e nded September 30, 2021 (in thousands) : Redeemable Balance at January 1, 2021 $ 39,600 Earnings attributable to noncontrolling interest 288 Measurement adjustment 329 Balance at March 31, 2021 $ 40,217 Earnings attributable to noncontrolling interest 640 Measurement adjustment 155 Balance at June 30, 2021 $ 41,012 Acquisition 85,075 Loss attributable to noncontrolling interest (4,577) Measurement adjustment 8,519 Balance at September 30, 2021 $ 130,029

Organization, Consolidation and

Organization, Consolidation and Presentation of Financial Statements (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation: The condensed consolidated financial statements include the accounts of Bright Health Group, Inc. and all subsidiaries and controlled companies. All intercompany balances and transactions are eliminated upon consolidation. The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our audited consolidated financial statements, unless the information contained in those disclosures materially changed or is required by GAAP. As such, the condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2020 included in the prospectus dated June 23, 2021 (File No.333-256286) (the “Prospectus”), as filed with the United States Securities and Exchange Commission (“SEC”) pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended. The accompanying condensed consolidated financial statements include all normal recurring adjustments necessary for fair presentation of the interim financial statements.
Use of Estimates	Use of Estimates: The preparation of our condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Our most significant estimates include medical costs payable, risk adjustment revenue and associated payables and receivables, valuation and impairment of goodwill and other intangible assets, valuation and impairment of investments and estimates of share-based compensation. Actual results could differ from these estimate s. For the three months ended September 30, 2021, we recognized a change in estimate for risk adjustment of $134.0 million as a result of updated data inputs used to calculate Individual and Family Plan (“IFP”) members’ expected full year risk scores, which resulted in an increase in risk adjustment
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements: There were no accounting pronouncements that were recently issued and not yet adopted or adopted since our audited consolidated financial statements that had, or are expected to have, a material impact on our consolidated financial position, results of operations, or cash flows.

ORGANIZATION AND BASIS OF PRE_2

ORGANIZATION AND BASIS OF PRESENTATION (Tables)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Operating Costs by Functional Classification	Operating Costs: Our operating costs, by functional classification for the three and nine months ended September 30, 2021 and 2020, are as follows (in thousands) : Three Months Ended Nine Months Ended 2021 2020 2021 2020 Compensation and fringe benefits $ 100,062 $ 35,588 $ 234,467 $ 92,589 Professional fees 61,483 20,745 143,248 53,381 Marketing and selling expense 69,443 15,941 183,636 39,056 Other operating expenses 78,802 25,105 217,739 75,624 Total operating costs $ 309,790 $ 97,379 $ 779,090 $ 260,650

BUSINESS COMBINATIONS (Tables)

BUSINESS COMBINATIONS (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Business Acquisitions, by Acquisition	The following table discloses the preliminary estimated fair values of assets and liabilities acquired by the Company in the Centrum acquisition (in thousands) : Accounts receivable $ 1,874 Prepaids and other current assets 627 Property and equipment 2,557 Intangible assets 102,370 Other assets 8,917 Total assets 116,345 Medical payables 19 Accounts payable 359 Other current liabilities 861 Other liabilities 11,636 Total liabilities 12,875 Net identified assets acquired 103,470 Goodwill 277,831 Redeemable noncontrolling interest (85,075) Total purchase consideration $ 296,226 The following table discloses the preliminary estimated fair values of assets and liabilities acquired by the Company in the CHP acquisition (in thousands) : Accounts receivable $ 16,361 Short-term investments 19,041 Prepaids and other current assets 25,520 Property and equipment 370 Intangible assets 102,000 Total assets 163,292 Medical costs payable 79,450 Accounts payable 2,371 Other current liabilities 17,212 Other liabilities 28,622 Total liabilities 127,655 Net identified assets acquired 35,637 Goodwill 236,037 Total purchase consideration $ 271,674 The following table discloses the preliminary estimated fair values of assets and liabilities acquired by the Company in the THNM and Zipnosis acquisitions (in thousands) : THNM Zipnosis Accounts receivable $ 714 $ 1,062 Short-term investments 4,677 — Prepaids and other current assets 8,337 141 Property and equipment — 232 Intangible assets 7,300 8,970 Long-term investments 13,081 — Other non-current assets 1,324 766 Total assets 35,433 11,171 Medical costs payable 13,268 — Accounts payable 14,663 136 Unearned revenue 3,645 120 Other current liabilities 2,682 665 Other liabilities 2,499 2,730 Total liabilities 36,757 3,651 Net identified assets acquired (1,324) 7,520 Goodwill 4,739 62,277 Total purchase consideration $ 3,415 $ 69,797 (in thousands) : Amount Recognized as of Measurement Amounts Recognized as of Accounts receivable $ 74,128 $ — $ 74,128 Prepaid and other currents assets 30,583 — 30,583 Property and equipment 4,375 — 4,375 Intangible assets 72,600 1,900 74,500 Other non-current assets 2,906 — 2,906 Total assets 184,592 1,900 186,492 Medical costs payable 119,408 — 119,408 Other current liabilities 51,744 174 51,918 Other liabilities 1,236 108 1,344 Total liabilities 172,388 282 172,670 Net identified assets acquired 12,204 1,618 13,822 Goodwill 197,886 (1,618) 196,268 Total purchase consideration $ 210,090 $ — $ 210,090
Business Acquisition, Pro Forma Information	The following pro forma financial information presents our revenue and net loss as if CHP had been included in the consolidated results of the Company for the nine months ended September 30, 2021 and the three and nine months ended September 30, 2020 (in thousands) : Pro Forma Consolidated Statements of Income (Loss) (Unaudited) Three Months Ended Nine Months Ended September 30, 2020 2021 2020 Revenue $ 502,378 $ 3,195,925 $ 1,263,016 Net Loss (49,157) (358,935) (70,971) The following pro forma financial information presents our revenue and net loss as if THNM and Zipnosis had been included in the consolidated results of the Company for the nine months ended September 30, 2021 and three and nine months ended September 30, 2020 (in thousands) : Pro Forma Consolidated Statements of Income (Loss) (Unaudited) Three Months Ended Nine Months Ended September 30, 2020 2021 2020 Revenue 384,797 $ 3,114,954 943,286 Net Loss (57,035) $ (372,315) (85,988)

INVESTMENTS (Tables)

INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Schedule of Debt Securities, Available-for-sale	The following is a summary of our investment securities as of September 30, 2021 and December 31, 2020 (in thousands) : September 30, 2021 Amortized Gross Gross Carrying Cash equivalents $ 271,984 $ 1 $ (1) $ 271,984 Available for sale: U.S. government and agency obligations 501,343 283 (376) 501,250 Corporate obligations 290,917 384 (106) 291,195 State and municipal obligations 15,437 51 (3) 15,485 Commercial paper 5,160 5 — 5,165 Certificates of deposit 26,809 — — 26,809 Mortgage-backed securities 2,533 — — 2,533 Other 12,876 1 (8) 12,869 Total available-for-sale securities 855,075 724 (493) 855,306 Held to maturity: U.S. government and agency obligations 7,745 — — 7,745 Certificates of deposit 1,447 — — 1,447 Total held-to-maturity securities 9,192 — — 9,192 Total investments $ 1,136,251 $ 725 $ (494) $ 1,136,482 December 31, 2020 Amortized Gross Gross Carrying Cash equivalents $ 153,743 $ — $ (3) $ 153,740 Available for sale: U.S. government and agency obligations 291,834 1,246 (1) 293,079 Corporate obligations 280,557 1,104 (30) 281,631 State and municipal obligations 18,459 107 — 18,566 Commercial paper 14,990 1 — 14,991 Certificates of deposit 53,504 2 (1) 53,505 Other 5,534 2 — 5,536 Total available-for-sale securities 664,878 2,462 (32) 667,308 Held to maturity: U.S. government and agency obligations 6,677 — — 6,677 Certificates of deposit 1,119 — — 1,119 Total held-to-maturity securities 7,796 — — 7,796 Total investments $ 826,417 $ 2,462 $ (35) $ 828,844
Schedule of Debt Securities, Held-to-maturity	The following is a summary of our investment securities as of September 30, 2021 and December 31, 2020 (in thousands) : September 30, 2021 Amortized Gross Gross Carrying Cash equivalents $ 271,984 $ 1 $ (1) $ 271,984 Available for sale: U.S. government and agency obligations 501,343 283 (376) 501,250 Corporate obligations 290,917 384 (106) 291,195 State and municipal obligations 15,437 51 (3) 15,485 Commercial paper 5,160 5 — 5,165 Certificates of deposit 26,809 — — 26,809 Mortgage-backed securities 2,533 — — 2,533 Other 12,876 1 (8) 12,869 Total available-for-sale securities 855,075 724 (493) 855,306 Held to maturity: U.S. government and agency obligations 7,745 — — 7,745 Certificates of deposit 1,447 — — 1,447 Total held-to-maturity securities 9,192 — — 9,192 Total investments $ 1,136,251 $ 725 $ (494) $ 1,136,482 December 31, 2020 Amortized Gross Gross Carrying Cash equivalents $ 153,743 $ — $ (3) $ 153,740 Available for sale: U.S. government and agency obligations 291,834 1,246 (1) 293,079 Corporate obligations 280,557 1,104 (30) 281,631 State and municipal obligations 18,459 107 — 18,566 Commercial paper 14,990 1 — 14,991 Certificates of deposit 53,504 2 (1) 53,505 Other 5,534 2 — 5,536 Total available-for-sale securities 664,878 2,462 (32) 667,308 Held to maturity: U.S. government and agency obligations 6,677 — — 6,677 Certificates of deposit 1,119 — — 1,119 Total held-to-maturity securities 7,796 — — 7,796 Total investments $ 826,417 $ 2,462 $ (35) $ 828,844
Schedule of Available-for-sale Investment With Gross Unrealized Losses	The fair value of available-for-sale investments, including those that are cash equivalents, with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position at September 30, 2021 and December 31, 2020 were as follows (in thousands) : September 30, 2021 Less Than 12 Months 12 Months or Greater Total Description of Investments Fair Unrealized Fair Unrealized Fair Unrealized Cash equivalents $ 9,643 $ (1) $ — $ — $ 9,643 $ (1) U.S. government and agency obligations 347,735 (376) — — 347,735 (376) Corporate obligations 137,456 (106) — — 137,456 (106) State and municipal obligations 2,812 (3) — — 2,812 (3) Other 10,950 (8) — — 10,950 (8) Total bonds $ 508,596 $ (494) $ — $ — $ 508,596 $ (494) December 31, 2020 Less Than 12 Months 12 Months or Greater Total Description of Investments Fair Unrealized Fair Unrealized Fair Unrealized Cash equivalents $ 25,007 $ (3) $ — $ — $ 25,007 $ (3) U.S. government and agency obligations 12,507 (1) — — 12,507 (1) Corporate obligations 121,006 (30) — — 121,006 (30) Commercial paper 999 — — — 999 — Certificates of deposit 14,003 (1) — — 14,003 (1) Total bonds $ 173,522 $ (35) $ — $ — $ 173,522 $ (35)
Schedule of Available-for-sale Securities by Contractual Maturity	As of September 30, 2021, the maturity of available-for-sale securities, by contractual maturity, reflected at amortized cost and fair value were as follows (in thousands) : Amortized Fair Due in one year or less $ 203,284 $ 203,614 Due after one year through five years 651,705 651,606 Due after five years through 10 years 86 86 Due after 10 years — — Total debt securities $ 855,075 $ 855,306

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables set forth our fair value measurements as of September 30, 2021 and December 31, 2020, for assets measured at fair value on a recurring basis (in thousands): September 30, 2021 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 209,727 $ 35,507 $ — $ 245,234 Fixed maturity securities, available for sale: U.S. government and agency obligations 358,202 143,048 — 501,250 Corporate obligations 2,234 288,961 — 291,195 State and municipal obligations — 15,485 — 15,485 Commercial paper — 5,165 — 5,165 Certificates of deposit 18,738 8,071 — 26,809 Mortgage-backed securities 2,533 — — 2,533 Other — 12,869 — 12,869 Total fixed maturity securities, available for sale: 381,707 473,599 — 855,306 Equity securities 149,144 — — 149,144 Total assets at fair value $ 740,578 $ 509,106 $ — $ 1,249,684 Liabilities Contingent consideration $ — $ — $ 7,079 $ 7,079 December 31, 2020 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 149,499 $ 4,019 $ — $ 153,518 Fixed maturity securities, available for sale: U.S. government and agency obligations 197,886 95,193 — 293,079 Corporate obligations — 281,631 — 281,631 State and municipal obligations — 18,566 — 18,566 Commercial paper — 14,991 — 14,991 Certificates of deposit — 53,505 — 53,505 Other — 5,536 — 5,536 Total assets at fair value $ 347,385 $ 473,441 $ — $ 820,826 Liabilities Contingent consideration $ — $ — $ 5,716 $ 5,716
Fair Value Disclosure of Asset and Liability Not Measured at Fair Value	The following tables set forth the Company’s fair value measurements as of September 30, 2021 and December 31, 2020, for certain financial instruments not measured at fair value on a recurring basis (in thousands) : September 30, 2021 Level 1 Level 2 Level 3 Total Cash equivalents, held to maturity $ 26,750 $ — $ — $ 26,750 Fixed maturity securities, held to maturity: U.S. government and agency obligations 7,768 — — 7,768 Certificates of deposit 1,447 — — 1,447 Total held to maturity $ 35,965 $ — $ — $ 35,965 December 31, 2020 Level 1 Level 2 Level 3 Total Cash equivalents, held to maturity $ 222 $ — $ — $ 222 Fixed maturity securities, held to maturity: U.S. government and agency obligations 6,732 — — 6,732 Certificates of deposit — 1,119 — 1,119 Total held to maturity $ 6,954 $ 1,119 $ — $ 8,073
Schedule of Changes in Fair Value of Contingent Consideration Liability	The following table presents the changes in fair value of the contingent consideration liability for the nine months ended September 30, 2021 and year ended December 31, 2020 (in thousands) : 2021 2020 Balance at beginning of period $ 5,716 $ 5,716 Change in fair value of contingent consideration 1,363 — Balance at end of period $ 7,079 $ 5,716

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in the carrying value of goodwill by reportable segment were as follows (in thousands) : Bright HealthCare NeueHealth Gross Carrying Cumulative Gross Carrying Cumulative Balance at December 31, 2020 $ 197,886 $ — $ 65,149 $ — Acquisitions 240,776 340,108 Purchase adjustments (1,618) — — — Balance at September 30, 2021 $ 437,044 $ — $ 405,257 $ —
Schedule of Finite-Lived Intangible Assets	The gross carrying value and accumulated amortization for definite-lived intangible assets were as follows (in thousands) : September 30, 2021 December 31, 2020 Gross Carrying Accumulated Amortization Gross Carrying Accumulated Amortization Customer relationships $ 209,321 $ 19,257 $ 117,451 $ 3,664 Trade names 99,231 5,057 38,161 1,604 Reacquired contract 59,000 3,278 — — Developed technology 6,200 443 — — Other 6,400 598 2,000 133 Total $ 380,152 $ 28,633 $ 157,612 $ 5,401
Schedule of Acquired Finite-Lived Intangible Assets by Major Class	The acquisition date fair values and weighted-average useful lives assigned to definite-lived intangible assets acquired during the nine months ended September 30, 2021 were as follows (in thousands) : Fair Value Weighted-Average Customer relationships $ 90,670 16.0 Trade names 60,370 14.9 Reacquired contract 59,000 4.5 Developed technology 6,200 7.0 Other 4,400 7.0 Total $ 220,640 9.8
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated amortization expense relating to intangible assets for the remainder of 2021 and for each of the next five full years ending December 31 is as follows (in thousands) : 2021 (October-December) $ 10,513 2022 42,050 2023 42,029 2024 41,890 2025 41,890 2026 26,323

MEDICAL COSTS PAYABLE (Tables)

MEDICAL COSTS PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2021
Insurance [Abstract]
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense	The following table shows the components of the change in medical costs payable for the nine months ended September 30 (in thousands) : 2021 2020 Medical costs payable - January 1 $ 249,777 $ 44,804 Incurred related to: Current year 2,647,719 685,637 Prior year 1,726 (9,297) Total incurred 2,649,445 676,340 Paid related to: Current year 2,074,602 610,161 Prior year 232,312 29,974 Total paid 2,306,914 640,135 Acquired claims liabilities 92,737 118,662 Medical costs payable - September 30 $ 685,045 $ 199,671 The table below details the components making up the medical costs payable as of September 30 (in thousands) : 2021 2020 Claims unpaid $ 42,488 $ 25,961 Provider incentive payable 69,274 10,391 Claims adjustment expense liability 12,413 2,572 Incurred but not reported 560,870 160,747 Total medical costs payable $ 685,045 $ 199,671

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The calculated value of each option award is estimated on the date of grant using a Black-Scholes option valuation model that used the following weighted-average assumptions for options granted during the nine months ended September 30, 2021: 2021 Risk-free interest rate 0.8 % Expected volatility 33.3 % Expected dividend rate 0.0 % Forfeiture rate 14.5 % Expected life in years 6.1
Schedule of Share-based Payment Arrangement, Option, Activity	The activity for the stock options for the nine months ended September 30, 2021 is as follows (in thousands, except exercise price and contractual life) : Shares Weighted-Average Weighted-Average Aggregate Outstanding at January 1, 2021 63,925 $ 1.47 8.7 $ 53,573 Granted 20,447 2.58 Exercised (9,373) 1.09 Forfeited (4,709) 1.75 Expired (11) 1.09 Outstanding at September 30, 2021 70,279 $ 1.83 8.5 $ 445,246
Share-based Payment Arrangement, Restricted Stock Unit, Activity	The following table summarizes RSU award activity for the nine months ended September 30, 2021 ( in thousands, except weighted average grant date fair value ) : RSU Number of RSUs Weighted Average Grant Date Fair Value Unvested RSUs at December 31, 2020 — $ — RSUs granted 364 9.11 RSUs canceled (19) 9.01 Unvested RSUs at September 30, 2021 345 $ 9.11
Share-based Payment Arrangement, Performance Shares, Activity	The following table summarizes PSU award activity for the nine months ended September 30, 2021 (in thousands, except weighted average grant date fair value) : PSU Number of PSUs Weighted Average Grant Date Fair Value Unvested PSUs at December 31, 2020 — $ — PSUs granted 14,700 9.30 PSUs canceled — — Unvested PSUs at September 30, 2021 14,700 $ 9.30

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30 (in thousands, except for per share amounts) : Three Months Ended September 30, Nine Months Ended 2021 2020 2021 2020 Net loss attributable to Bright Health Group, Inc. common shareholders $ (300,664) $ (59,256) $ (370,344) $ (84,610) Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted 630,378 136,337 312,294 135,926 Net loss per share attributable to common stockholders, basic and diluted $ (0.48) $ (0.43) $ (1.19) $ (0.62)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive effect for the nine months ended September 30 (in thousands) : Nine Months Ended 2021 2020 Redeemable convertible preferred stock (as converted to common stock) — 411,238 Stock options to purchase common stock 70,279 58,224 Total 70,279 469,462

SEGMENT AND GEOGRAPHICAL INFO_2

SEGMENT AND GEOGRAPHICAL INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of Reportable Segment Financial Information	The following tables present the reportable segment financial information for the three and nine months ended September 30, 2021 and 2020 (in thousands) : Three Months Ended September 30, 2021 Bright NeueHealth Eliminations Consolidated Premium revenue $ 994,586 $ 25,647 $ — $ 1,020,233 Service revenue (61) 11,140 — 11,079 Investment income 1,087 46,258 — 47,345 Total unaffiliated revenue 995,612 83,045 — 1,078,657 Affiliated revenue — 139,759 (139,759) — Total segment revenue 995,612 222,804 (139,759) 1,078,657 Operating income (loss) (303,271) 6,990 — (296,281) Depreciation and amortization $ 4,584 $ 9,621 $ — $ 14,205 Three Months Ended September 30, 2020 Bright NeueHealth Eliminations Consolidated Premium revenue $ 343,472 $ 1,954 $ — $ 345,426 Service revenue — 4,920 — 4,920 Investment income 1,774 — — 1,774 Total unaffiliated revenue 345,246 6,874 — 352,120 Affiliated revenue — 2,727 (2,727) — Total segment revenue 345,246 9,601 (2,727) 352,120 Operating income (loss) (57,263) (1,993) — (59,256) Depreciation and amortization $ 2,274 $ 404 $ — $ 2,678 Nine Months Ended September 30, 2021 Bright NeueHealth Eliminations Consolidated Premium revenue $ 2,860,270 $ 62,680 $ — $ 2,922,950 Service revenue 29 31,573 — 31,602 Investment income 3,491 109,012 — 112,503 Total unaffiliated revenue 2,863,790 203,265 — 3,067,055 Affiliated revenue — 182,392 (182,392) — Total segment revenue 2,863,790 385,657 (182,392) 3,067,055 Operating income (loss) (443,450) 65,291 — (378,159) Depreciation and amortization $ 11,524 $ 14,457 $ — $ 25,981 Nine Months Ended September 30, 2020 Bright NeueHealth Eliminations Consolidated Premium revenue $ 821,185 $ 5,950 $ — $ 827,135 Service revenue — 13,344 — 13,344 Investment income 7,063 — — 7,063 Total unaffiliated revenue 828,248 19,294 — 847,542 Affiliated revenue — 8,176 (8,176) — Total segment revenue 828,248 27,470 (8,176) 847,542 Operating income (loss) (88,427) (5,345) — (93,772) Depreciation and amortization $ 4,131 $ 1,419 $ — $ 5,550

REDEEMABLE NONCONTROLLING INT_2

REDEEMABLE NONCONTROLLING INTEREST (Tables)	9 Months Ended
	Sep. 30, 2021
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interest	The following table provides details of our redeemable noncontrolling interest activity for the three and nine months e nded September 30, 2021 (in thousands) : Redeemable Balance at January 1, 2021 $ 39,600 Earnings attributable to noncontrolling interest 288 Measurement adjustment 329 Balance at March 31, 2021 $ 40,217 Earnings attributable to noncontrolling interest 640 Measurement adjustment 155 Balance at June 30, 2021 $ 41,012 Acquisition 85,075 Loss attributable to noncontrolling interest (4,577) Measurement adjustment 8,519 Balance at September 30, 2021 $ 130,029

ORGANIZATION AND BASIS OF PRE_3

ORGANIZATION AND BASIS OF PRESENTATION - Narrative (Details) $ / shares in Units, $ in Thousands	Jun. 28, 2021USD ($)$ / sharesshares	Jun. 02, 2021	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)$ / shares
Subsidiary, Sale of Stock [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001		$ 0.0001		$ 0.0001		$ 0.0001
Underwriting discounts and commissions | $					$ 6,686	$ 0
Common stock issued, conversion of convertible securities (in shares) | shares	427,897,381
Convertible preferred stock, par value (in dollars per share) | $ / shares			$ 0.0001		$ 0.0001		$ 0.0001
Stock split, conversion ratio		3
Risk adjustment payable | $			$ 548,352		$ 548,352		$ 187,777
Premium revenue | $			(1,020,233)	$ (345,426)	(2,922,950)	$ (827,135)
Updated Risk Score Data
Subsidiary, Sale of Stock [Line Items]
Risk adjustment payable | $			134,000		$ 134,000
Premium revenue | $			$ 134,000
Series A Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
Series B Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in dollars per share) | $ / shares	0.0001
Series C Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in dollars per share) | $ / shares	0.0001
Series D Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in dollars per share) | $ / shares	0.0001
Series E Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
IPO
Subsidiary, Sale of Stock [Line Items]
Number of shares issued (in shares) | shares	51,350,000
Price per share of common stock (in dollars per share) | $ / shares	$ 18
Proceeds from sale of stock | $	$ 887,300
Underwriting discounts and commissions | $	37,000
Deferred offering costs | $	$ 6,700

ORGANIZATION AND BASIS OF PRE_4

ORGANIZATION AND BASIS OF PRESENTATION - Schedule of Operating Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Compensation and fringe benefits	$ 100,062	$ 35,588	$ 234,467	$ 92,589
Professional fees	61,483	20,745	143,248	53,381
Marketing and selling expense	69,443	15,941	183,636	39,056
Other operating expenses	78,802	25,105	217,739	75,624
Operating costs	$ 309,790	$ 97,379	$ 779,090	$ 260,650

BUSINESS COMBINATIONS - Narrati

BUSINESS COMBINATIONS - Narrative (Details) $ in Thousands	Jul. 01, 2021USD ($)healthCenter	Apr. 01, 2021USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Apr. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2021USD ($)
Business Acquisition [Line Items]
Weighted average useful life								9 years 9 months 18 days
Intangible assets acquired								$ 220,640
Trade Names
Business Acquisition [Line Items]
Weighted average useful life								14 years 10 months 24 days
Intangible assets acquired								$ 60,370
Customer Relationships
Business Acquisition [Line Items]
Weighted average useful life								16 years
Intangible assets acquired								$ 90,670
Reacquired contract
Business Acquisition [Line Items]
Weighted average useful life								4 years 6 months
Intangible assets acquired								$ 59,000
Developed Technology
Business Acquisition [Line Items]
Weighted average useful life								7 years
Intangible assets acquired								$ 6,200
Centrum
Business Acquisition [Line Items]
Voting interest acquired	75.00%
Payments to acquire business, gross	$ 222,400
Equity interest issued	75,000
Total consideration	296,200
Cash acquired	$ 1,200
Number of health centers | healthCenter	17
Transaction costs						$ 1,000		1,000
Centrum | Trade Names
Business Acquisition [Line Items]
Weighted average useful life	15 years
Centrum | Customer Relationships | Minimum
Business Acquisition [Line Items]
Weighted average useful life	2 years
Centrum | Customer Relationships | Maximum
Business Acquisition [Line Items]
Weighted average useful life	15 years
Centrum | Reacquired contract
Business Acquisition [Line Items]
Weighted average useful life	4 years 6 months
CHP
Business Acquisition [Line Items]
Payments to acquire business, gross		$ 276,000
Equity interest issued		79,800
Total consideration		271,700
Cash acquired		$ 84,100
Transaction costs								200			$ 1,400
Pro forma, revenue							$ 502,378	3,195,925	$ 1,263,016
Pro forma, net loss							$ (49,157)	(358,935)	(70,971)
CHP | Trade Names
Business Acquisition [Line Items]
Weighted average useful life		15 years
CHP | Customer Relationships
Business Acquisition [Line Items]
Weighted average useful life		10 years
CHP | Provider Network
Business Acquisition [Line Items]
Weighted average useful life		7 years
THNM
Business Acquisition [Line Items]
Payments to acquire business, gross			$ 27,500
Total consideration			3,400
Cash acquired			$ 24,100
THNM | Trade Names
Business Acquisition [Line Items]
Weighted average useful life			15 years
THNM | Customer Relationships | Minimum
Business Acquisition [Line Items]
Weighted average useful life			10 years
THNM | Customer Relationships | Maximum
Business Acquisition [Line Items]
Weighted average useful life			14 years
THNM | Provider Network
Business Acquisition [Line Items]
Weighted average useful life			7 years
Zipnosis
Business Acquisition [Line Items]
Payments to acquire business, gross			$ 73,000
Equity interest issued			55,100
Total consideration			69,800
Cash acquired			3,200
Transaction costs						$ 500		$ 500
Tangible net equity adjustment			$ 500
Zipnosis | Trade Names
Business Acquisition [Line Items]
Weighted average useful life			5 years
Zipnosis | Customer Relationships
Business Acquisition [Line Items]
Weighted average useful life			15 years
Zipnosis | Developed Technology
Business Acquisition [Line Items]
Weighted average useful life			7 years
PMA
Business Acquisition [Line Items]
Voting interest acquired				62.00%						62.00%
Total consideration				$ 74,200
BND
Business Acquisition [Line Items]
Payments to acquire business, gross					$ 206,900
Equity interest issued					80,000
Total consideration					210,100
Cash acquired					32,800
Transaction costs										$ 3,800
Escrow adjustment					$ 44,000
Pro forma, revenue									1,000,000
Pro forma, net loss									$ (100,900)
BND | Trade Names
Business Acquisition [Line Items]
Weighted average useful life					15 years
Intangible assets acquired					$ 25,600
BND | Customer Relationships
Business Acquisition [Line Items]
Weighted average useful life					12 years
Intangible assets acquired					$ 46,900
BND | Provider Network
Business Acquisition [Line Items]
Weighted average useful life					10 years
Intangible assets acquired					$ 2,000

BUSINESS COMBINATIONS - Schedul

BUSINESS COMBINATIONS - Schedule of Business Acquisitions (Details) - USD ($) $ in Thousands	17 Months Ended
	Sep. 30, 2021	Jul. 01, 2021	Apr. 01, 2021	Mar. 31, 2021	Dec. 31, 2020	Apr. 30, 2020
Business Acquisition, Date of Acquisition [Abstract]
Goodwill	$ 842,301				$ 263,035
Centrum
Business Acquisition, Date of Acquisition [Abstract]
Accounts receivable		$ 1,874
Prepaids and other current assets		627
Property and equipment		2,557
Intangible assets		102,370
Other non-current assets		8,917
Total assets		116,345
Medical costs payable		19
Accounts payable		359
Other current liabilities		861
Other liabilities		11,636
Total liabilities		12,875
Net identified assets acquired		103,470
Goodwill		277,831
Redeemable noncontrolling interest		(85,075)
Total purchase consideration		$ 296,226
CHP
Business Acquisition, Date of Acquisition [Abstract]
Accounts receivable			$ 16,361
Short-term investments			19,041
Prepaids and other current assets			25,520
Property and equipment			370
Intangible assets			102,000
Total assets			163,292
Medical costs payable			79,450
Accounts payable			2,371
Other current liabilities			17,212
Other liabilities			28,622
Total liabilities			127,655
Net identified assets acquired			35,637
Goodwill			236,037
Total purchase consideration			$ 271,674
THNM
Business Acquisition, Date of Acquisition [Abstract]
Accounts receivable				$ 714
Short-term investments				4,677
Prepaids and other current assets				8,337
Property and equipment				0
Intangible assets				7,300
Long-term investments				13,081
Other non-current assets				1,324
Total assets				35,433
Medical costs payable				13,268
Accounts payable				14,663
Unearned revenue				3,645
Other current liabilities				2,682
Other liabilities				2,499
Total liabilities				36,757
Net identified assets acquired				(1,324)
Goodwill				4,739
Total purchase consideration				3,415
Zipnosis
Business Acquisition, Date of Acquisition [Abstract]
Accounts receivable				1,062
Short-term investments				0
Prepaids and other current assets				141
Property and equipment				232
Intangible assets				8,970
Long-term investments				0
Other non-current assets				766
Total assets				11,171
Medical costs payable				0
Accounts payable				136
Unearned revenue				120
Other current liabilities				665
Other liabilities				2,730
Total liabilities				3,651
Net identified assets acquired				7,520
Goodwill				62,277
Total purchase consideration				$ 69,797
BND
Business Acquisition, Date of Acquisition [Abstract]
Accounts receivable	74,128					$ 74,128
Measurement Period Adjustments, Accounts receivable	0
Prepaids and other current assets	30,583					30,583
Measurement Period Adjustments, Prepaid and other current assets	0
Property and equipment	4,375					4,375
Measurement Period Adjustments, Property and equipment	0
Intangible assets	74,500					72,600
Measurement Period Adjustments, Intangible assets	1,900
Other non-current assets	2,906					2,906
Measurement Period Adjustments, Other non-current assets	0
Total assets	186,492					184,592
Measurement Period Adjustments, Total assets	1,900
Medical costs payable	119,408					119,408
Measurement Period Adjustments, Medical costs payable	0
Other current liabilities	51,918					51,744
Measurement Period Adjustments, Other current liabilities	174
Other liabilities	1,344					1,236
Measurement Period Adjustments, Other liabilities	108
Total liabilities	172,670					172,388
Measurement Period Adjustments, Total liabilities	282
Net identified assets acquired	13,822					12,204
Measurement Period Adjustments, Net identified assets acquired	1,618
Goodwill	196,268					197,886
Measurement Period Adjustments, Goodwill	(1,618)
Total purchase consideration	210,090					$ 210,090
Measurement Period Adjustments, Total purchase consideration	$ 0

BUSINESS COMBINATIONS - Sched_2

BUSINESS COMBINATIONS - Schedule of Pro Forma Revenue and Net Loss (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
CHP
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenue	$ 502,378	$ 3,195,925	$ 1,263,016
Net Loss	(49,157)	(358,935)	(70,971)
THNM And Zipnosis
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenue	384,797	3,114,954	943,286
Net Loss	$ (57,035)	$ (372,315)	$ (85,988)

INVESTMENTS - Schedule of Inves

INVESTMENTS - Schedule of Investment Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Cash equivalents, Amortized Cost	$ 271,984	$ 153,743
Cash equivalents, Gross Unrealized Gains	1	0
Cash equivalents, Gross Unrealized Losses	(1)	(3)
Cash equivalents, Carrying Value	271,984	153,740
Amortized Cost	855,075	664,878
Gross Unrealized Gains	724	2,462
Gross Unrealized Losses	(493)	(32)
Available for sale	855,306	667,308
Debt Securities, Held-to-maturity, Securities [Line Items]
Amortized Cost	9,192	7,796
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Amortized Cost, Total investments	1,136,251	826,417
Gross Unrealized Gains, Total investments	725	2,462
Gross Unrealized Losses, Total investments	(494)	(35)
Carrying Value, Total investments	1,136,482	828,844
U.S. government and agency obligations
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	501,343	291,834
Gross Unrealized Gains	283	1,246
Gross Unrealized Losses	(376)	(1)
Available for sale	501,250	293,079
Debt Securities, Held-to-maturity, Securities [Line Items]
Amortized Cost	7,745	6,677
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Corporate obligations
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	290,917	280,557
Gross Unrealized Gains	384	1,104
Gross Unrealized Losses	(106)	(30)
Available for sale	291,195	281,631
State and municipal obligations
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	15,437	18,459
Gross Unrealized Gains	51	107
Gross Unrealized Losses	(3)	0
Available for sale	15,485	18,566
Commercial paper
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	5,160	14,990
Gross Unrealized Gains	5	1
Gross Unrealized Losses	0	0
Available for sale	5,165	14,991
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	26,809	53,504
Gross Unrealized Gains	0	2
Gross Unrealized Losses	0	(1)
Available for sale	26,809	53,505
Debt Securities, Held-to-maturity, Securities [Line Items]
Amortized Cost	1,447	1,119
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	2,533
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Available for sale	2,533
Other
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	12,876	5,534
Gross Unrealized Gains	1	2
Gross Unrealized Losses	(8)	0
Available for sale	$ 12,869	$ 5,536

INVESTMENTS - Schedule of Inv_2

INVESTMENTS - Schedule of Investments in Continuous Loss Position (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	$ 508,596	$ 173,522
Available-for-sale securities, less than 12 months, Unrealized Losses	(494)	(35)
Available-for-sale securities, 12 months or greater, Fair Value	0	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0	0
Available-for-sale securities, Fair Value	508,596	173,522
Available-for-sale securities, Unrealized Losses	(494)	(35)
Cash equivalents
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	9,643	25,007
Available-for-sale securities, less than 12 months, Unrealized Losses	(1)	(3)
Available-for-sale securities, 12 months or greater, Fair Value	0	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0	0
Available-for-sale securities, Fair Value	9,643	25,007
Available-for-sale securities, Unrealized Losses	(1)	(3)
U.S. government and agency obligations | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	347,735	12,507
Available-for-sale securities, less than 12 months, Unrealized Losses	(376)	(1)
Available-for-sale securities, 12 months or greater, Fair Value	0	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0	0
Available-for-sale securities, Fair Value	347,735	12,507
Available-for-sale securities, Unrealized Losses	(376)	(1)
Corporate obligations | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	137,456	121,006
Available-for-sale securities, less than 12 months, Unrealized Losses	(106)	(30)
Available-for-sale securities, 12 months or greater, Fair Value	0	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0	0
Available-for-sale securities, Fair Value	137,456	121,006
Available-for-sale securities, Unrealized Losses	(106)	(30)
State and municipal obligations | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	2,812
Available-for-sale securities, less than 12 months, Unrealized Losses	(3)
Available-for-sale securities, 12 months or greater, Fair Value	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0
Available-for-sale securities, Fair Value	2,812
Available-for-sale securities, Unrealized Losses	(3)
Commercial paper | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value		999
Available-for-sale securities, less than 12 months, Unrealized Losses		0
Available-for-sale securities, 12 months or greater, Fair Value		0
Available-for-sale securities, 12 months or greater, Unrealized Losses		0
Available-for-sale securities, Fair Value		999
Available-for-sale securities, Unrealized Losses		0
Certificates of deposit | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value		14,003
Available-for-sale securities, less than 12 months, Unrealized Losses		(1)
Available-for-sale securities, 12 months or greater, Fair Value		0
Available-for-sale securities, 12 months or greater, Unrealized Losses		0
Available-for-sale securities, Fair Value		14,003
Available-for-sale securities, Unrealized Losses		$ (1)
Other | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	10,950
Available-for-sale securities, less than 12 months, Unrealized Losses	(8)
Available-for-sale securities, 12 months or greater, Fair Value	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0
Available-for-sale securities, Fair Value	10,950
Available-for-sale securities, Unrealized Losses	$ (8)

INVESTMENTS - Narrative (Detail

INVESTMENTS - Narrative (Details) $ in Thousands, shares in Millions	Apr. 01, 2021USD ($)shares	Sep. 30, 2021USD ($)investment	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)investment	Sep. 30, 2020USD ($)	Dec. 31, 2020investment
Debt Securities, Available-for-sale [Line Items]
Number of securities in unrealized loss position | investment		744		744		117
Number of investments | investment		1,859		1,859		1,917
Investment income		$ 47,345	$ 1,774	$ 112,503	$ 7,063
Realized gains on fixed maturity securities				400	100
Equity securities purchased (in shares) | shares	1.6
Payments to acquire equity securities	$ 40,100
Equity security market value		149,100		149,100
Unrealized gain on equity securities		$ 46,300		109,000
Debt Securities
Debt Securities, Available-for-sale [Line Items]
Investment income				$ 3,500	$ 7,100

INVESTMENTS - Schedule Of Avail

INVESTMENTS - Schedule Of Available-for-sale Securities Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]
Due in one year or less	$ 203,284
Due after one year through five years	651,705
Due after five years through 10 years	86
Due after 10 years	0
Amortized Cost	855,075	$ 664,878
Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]
Due in one year or less	203,614
Due after one year through five years	651,606
Due after five years through 10 years	86
Due after 10 years	0
Carrying Value	$ 855,306	$ 667,308

FAIR VALUE MEASUREMENTS - Sched

FAIR VALUE MEASUREMENTS - Schedule of Fair Value Measurement for Assets on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 26,750	$ 222
Available for sale	855,306	667,308
U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	501,250	293,079
Corporate obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	291,195	281,631
State and municipal obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	15,485	18,566
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	5,165	14,991
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	26,809	53,505
Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	2,533
Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	12,869	5,536
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	26,750	222
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	245,234	153,518
Available for sale	855,306
Equity securities	149,144
Total assets at fair value	1,249,684	820,826
Contingent consideration	7,079	5,716
Fair Value, Recurring | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	501,250	293,079
Fair Value, Recurring | Corporate obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	291,195	281,631
Fair Value, Recurring | State and municipal obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	15,485	18,566
Fair Value, Recurring | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	5,165	14,991
Fair Value, Recurring | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	26,809	53,505
Fair Value, Recurring | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	2,533
Fair Value, Recurring | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	12,869	5,536
Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	209,727	149,499
Available for sale	381,707
Equity securities	149,144
Total assets at fair value	740,578	347,385
Contingent consideration	0	0
Fair Value, Recurring | Level 1 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	358,202	197,886
Fair Value, Recurring | Level 1 | Corporate obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	2,234	0
Fair Value, Recurring | Level 1 | State and municipal obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	0	0
Fair Value, Recurring | Level 1 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	0	0
Fair Value, Recurring | Level 1 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	18,738	0
Fair Value, Recurring | Level 1 | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	2,533
Fair Value, Recurring | Level 1 | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	0	0
Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	35,507	4,019
Available for sale	473,599
Equity securities	0
Total assets at fair value	509,106	473,441
Contingent consideration	0	0
Fair Value, Recurring | Level 2 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	143,048	95,193
Fair Value, Recurring | Level 2 | Corporate obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	288,961	281,631
Fair Value, Recurring | Level 2 | State and municipal obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	15,485	18,566
Fair Value, Recurring | Level 2 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	5,165	14,991
Fair Value, Recurring | Level 2 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	8,071	53,505
Fair Value, Recurring | Level 2 | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	0
Fair Value, Recurring | Level 2 | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	12,869	5,536
Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Available for sale	0
Equity securities	0
Total assets at fair value	0	0
Contingent consideration	7,079	5,716
Fair Value, Recurring | Level 3 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	0	0
Fair Value, Recurring | Level 3 | Corporate obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	0	0
Fair Value, Recurring | Level 3 | State and municipal obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	0	0
Fair Value, Recurring | Level 3 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	0	0
Fair Value, Recurring | Level 3 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	0	0
Fair Value, Recurring | Level 3 | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	0
Fair Value, Recurring | Level 3 | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Sch_2

FAIR VALUE MEASUREMENTS - Schedule of Fair Value Measurement of Financial Instruments Not Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 26,750	$ 222
Total held to maturity	35,965	8,073
U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	7,768	6,732
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	1,447	1,119
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	26,750	222
Total held to maturity	35,965	6,954
Level 1 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	7,768	6,732
Level 1 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	1,447	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total held to maturity	0	1,119
Level 2 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	0	0
Level 2 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	0	1,119
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total held to maturity	0	0
Level 3 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	0	0
Level 3 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Sch_3

FAIR VALUE MEASUREMENTS - Schedule of Change in Fair Value of Contingent Consideration (Details) - Contingent Consideration Liability - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 5,716	$ 5,716
Change in fair value of contingent consideration	1,363	0
Ending balance	$ 7,079	$ 5,716

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Bright HealthCare
Goodwill [Roll Forward]
Gross Carrying Amount, Beginning balance	$ 197,886
Gross Carrying Amount, Acquisitions	240,776
Goodwill, Purchase adjustments	(1,618)
Gross Carrying Amount, Ending balance	437,044
Cumulative Impairment, Beginning balance	0
Cumulative Impairment, Ending balance	0
NeueHealth
Goodwill [Roll Forward]
Gross Carrying Amount, Beginning balance	65,149
Gross Carrying Amount, Acquisitions	340,108
Goodwill, Purchase adjustments	0
Gross Carrying Amount, Ending balance	405,257
Cumulative Impairment, Beginning balance	0
Cumulative Impairment, Ending balance	$ 0

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Schedule of Definite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 380,152	$ 157,612
Accumulated Amortization	28,633	5,401
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	209,321	117,451
Accumulated Amortization	19,257	3,664
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	99,231	38,161
Accumulated Amortization	5,057	1,604
Reacquired contract
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	59,000	0
Accumulated Amortization	3,278	0
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,200	0
Accumulated Amortization	443	0
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,400	2,000
Accumulated Amortization	$ 598	$ 133

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Schedule of Finite-lived Assets Useful Lives (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 220,640
Weighted-Average Useful Life (in years)	9 years 9 months 18 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 90,670
Weighted-Average Useful Life (in years)	16 years
Trade names
Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 60,370
Weighted-Average Useful Life (in years)	14 years 10 months 24 days
Reacquired contract
Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 59,000
Weighted-Average Useful Life (in years)	4 years 6 months
Developed technology
Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 6,200
Weighted-Average Useful Life (in years)	7 years
Other
Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 4,400
Weighted-Average Useful Life (in years)	7 years

GOODWILL AND INTANGIBLE ASSET_5

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 13,300	$ 1,800	$ 23,200	$ 3,600
2021 (October-December)	10,513		10,513
2022	42,050		42,050
2023	42,029		42,029
2024	41,890		41,890
2025	41,890		41,890
2026	$ 26,323		$ 26,323

MEDICAL COSTS PAYABLE - Change

MEDICAL COSTS PAYABLE - Change in Medical Costs Payable (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Beginning balance	$ 249,777	$ 44,804
Incurred related to:
Current year	2,647,719	685,637
Prior year	1,726	(9,297)
Total incurred	2,649,445	676,340
Paid related to:
Current year	2,074,602	610,161
Prior year	232,312	29,974
Total paid	2,306,914	640,135
Acquired claims liabilities	92,737	118,662
Ending balance	$ 685,045	$ 199,671

MEDICAL COSTS PAYABLE - Narrati

MEDICAL COSTS PAYABLE - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Insurance [Abstract]
Medical costs payable, increase (decrease) to prior years	$ 1.7	$ (9.3)

MEDICAL COSTS PAYABLE - Compone

MEDICAL COSTS PAYABLE - Components of Medical Costs Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Insurance [Abstract]
Claims unpaid	$ 42,488		$ 25,961
Provider incentive payable	69,274		10,391
Claims adjustment expense liability	12,413		2,572
Incurred but not reported	560,870		160,747
Total medical costs payable	$ 685,045	$ 249,777	$ 199,671	$ 44,804

SHORT-TERM BORROWINGS (Details)

SHORT-TERM BORROWINGS (Details)	Aug. 02, 2021USD ($)	Mar. 01, 2021USD ($)	Jun. 30, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Line of Credit Facility [Line Items]
Proceeds from short-term borrowings				$ 200,000,000	$ 0
Revolving Credit Facility | Line of Credit
Line of Credit Facility [Line Items]
Revolving credit facility		$ 350,000,000
IPO net proceeds requirement	$ 850,000,000	$ 1,000,000,000
Debt to capitalization ration before qualified IPO		0.25
Debt to capitalization ratio after qualified IPO		0.30
Debt to capitalization ratio	0.25
Proceeds from short-term borrowings			$ 200,000,000
Interest and other costs			$ 3,200,000

SHARE-BASED COMPENSATION - Narr

SHARE-BASED COMPENSATION - Narrative (Details) $ / shares in Units, $ in Millions	3 Months Ended	6 Months Ended	9 Months Ended
	Sep. 30, 2021USD ($)shares	Jun. 30, 2021	Sep. 30, 2021USD ($)vestingTranche$ / sharesshares	Sep. 30, 2020USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares) | shares	42,000,000		42,000,000
Number of shares available for grant (in shares) | shares	26,800,000		26,800,000
Share-based compensation expense			$ 43.2	$ 3.7
Weighted-average grant date fair value of stock options granted (in dollars per share) | $ / shares			$ 10.86
Unrecognized compensation expense	$ 150.7		$ 150.7
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Option grants expiration	10 years
Unrecognized compensation expense, weighted average recognition period			3 years 4 months 24 days
RSU's
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 0.2		$ 0.2
Vesting period			3 years
Unrecognized compensation expense, weighted average recognition period			2 years 8 months 12 days
Unrecognized compensation expense, other than options	2.5		$ 2.5
Granted (in shares) | shares			364,000
PSU's
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	10		$ 10.3
Unrecognized compensation expense, weighted average recognition period			2 years 8 months 12 days
Unrecognized compensation expense, other than options	$ 108.5		$ 108.5
Granted (in shares) | shares			14,700,000
Number of vesting tranches | vestingTranche			4
Service period			3 years
Tranche one | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting		25.00%
Vesting period		1 year
Tranche two | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		36 months

SHARE-BASED COMPENSATION - Sche

SHARE-BASED COMPENSATION - Schedule of Stock Option Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	0.80%
Expected volatility	33.30%
Expected dividend rate	0.00%
Forfeiture rate	14.50%
Expected life in years	6 years 1 month 6 days

SHARE-BASED COMPENSATION - Sc_2

SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Shares
Beginning balance (in shares)	63,925
Granted (in shares)	20,447
Exercised (in shares)	(9,373)
Forfeited (in shares)	(4,709)
Expired (in shares)	(11)
Ending balance (in shares)	70,279	63,925
Weighted-Average Exercise Price
Beginning balance (in dollars per share)	$ 1.47
Granted (in dollars per share)	2.58
Exercised (in dollars per share)	1.09
Forfeited (in dollars per share)	1.75
Expired (in dollars per share)	1.09
Ending balance (in dollars per share)	$ 1.83	$ 1.47
Aggregate Intrinsic Value
Beginning balance	$ 53,573
Ending balance	$ 445,246	$ 53,573
Weighted-Average Remaining Contractual Life (In Years)	8 years 6 months	8 years 8 months 12 days

SHARE-BASED COMPENSATION - Sc_3

SHARE-BASED COMPENSATION - Schedule of RSU and PSU Activity (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
RSU's
Number of Awards
Beginning balance (in shares) | shares	0
Granted (in shares) | shares	364,000
Canceled (in shares) | shares	(19,000)
Ending balance (in shares) | shares	345,000
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 0
Granted (in dollars per share) | $ / shares	9.11
Canceled (in dollars per share) | $ / shares	9.01
Ending balance (in dollars per share) | $ / shares	$ 9.11
PSU's
Number of Awards
Beginning balance (in shares) | shares	0
Granted (in shares) | shares	14,700,000
Canceled (in shares) | shares	0
Ending balance (in shares) | shares	14,700,000
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 0
Granted (in dollars per share) | $ / shares	9.30
Canceled (in dollars per share) | $ / shares	0
Ending balance (in dollars per share) | $ / shares	$ 9.30

NET LOSS PER SHARE - Schedule o

NET LOSS PER SHARE - Schedule of Net Loss Per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net loss attributable to Bright Health Group, Inc. common shareholders, basic	$ (300,664)	$ (59,256)	$ (370,344)	$ (84,610)
Net loss attributable to Bright Health Group, Inc. common shareholders, diluted	$ (300,664)	$ (59,256)	$ (370,344)	$ (84,610)
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic (in shares)	630,378	136,337	312,294	135,926
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, diluted (in shares)	630,378	136,337	312,294	135,926
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.48)	$ (0.43)	$ (1.19)	$ (0.62)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.48)	$ (0.43)	$ (1.19)	$ (0.62)

NET LOSS PER SHARE - Schedule_2

NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded From Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	70,279,000	469,462,000
Redeemable convertible preferred stock (as converted to common stock)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	0	411,238,000
Stock options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	70,279,000	58,224,000

SEGMENT AND GEOGRAPHICAL INFO_3

SEGMENT AND GEOGRAPHICAL INFORMATION - Narrative (Details)	9 Months Ended
	Sep. 30, 2021segment
Segment Reporting [Abstract]
Number of reportable segments	2

SEGMENT AND GEOGRAPHICAL INFO_4

SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Premium revenue	$ 1,020,233	$ 345,426	$ 2,922,950	$ 827,135
Service revenue	11,079	4,920	31,602	13,344
Investment income	47,345	1,774	112,503	7,063
Total revenue	1,078,657	352,120	3,067,055	847,542
Operating income (loss)	(296,281)	(59,256)	(378,159)	(93,772)
Depreciation and amortization	14,205	2,678	25,981	5,550
Bright HealthCare
Segment Reporting Information [Line Items]
Premium revenue	994,586	343,472	2,860,270	821,185
Service revenue	(61)	0	29	0
Investment income	1,087	1,774	3,491	7,063
Total revenue	995,612	345,246	2,863,790	828,248
NeueHealth
Segment Reporting Information [Line Items]
Premium revenue	25,647	1,954	62,680	5,950
Service revenue	11,140	4,920	31,573	13,344
Investment income	46,258	0	109,012	0
Total revenue	83,045	6,874	203,265	19,294
Operating Segments | Bright HealthCare
Segment Reporting Information [Line Items]
Total revenue	995,612	345,246	2,863,790	828,248
Operating income (loss)	(303,271)	(57,263)	(443,450)	(88,427)
Depreciation and amortization	4,584	2,274	11,524	4,131
Operating Segments | NeueHealth
Segment Reporting Information [Line Items]
Total revenue	222,804	9,601	385,657	27,470
Operating income (loss)	6,990	(1,993)	65,291	(5,345)
Depreciation and amortization	9,621	404	14,457	1,419
Intersegment Eliminations
Segment Reporting Information [Line Items]
Total revenue	(139,759)	(2,727)	(182,392)	(8,176)
Intersegment Eliminations | NeueHealth
Segment Reporting Information [Line Items]
Total revenue	$ (139,759)	$ (2,727)	$ (182,392)	$ (8,176)

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 73	$ 0	$ (18,225)	$ (9,162)

REDEEMABLE NONCONTROLLING INT_3

REDEEMABLE NONCONTROLLING INTEREST - Narrative (Details)	Jul. 01, 2021
Controlling Interest Holder | Centrum
Noncontrolling Interest [Line Items]
Ownership percentage	25.00%

REDEEMABLE NONCONTROLLING INT_4

REDEEMABLE NONCONTROLLING INTEREST - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance	$ 41,012	$ 40,217	$ 39,600
Acquisition	85,075
Earnings (Loss) attributable to noncontrolling interest	(4,577)	640	288
Measurement adjustment	8,519	155	329
Ending balance	$ 130,029	$ 41,012	$ 40,217